Document:

<PAGE>

EXECUTION                                                           Exhibit 10.1

          Confidential treatment has been requested for portions of this
          exhibit. The copy filed herewith omits the information subject to the
          confidentiality request. Omissions are designated as **. A complete
          version of this exhibit has been filed separately with the Securities
          and Exchange Commission.

                               LICENSE AGREEMENT

                          dated as of April 13, 2002

                                by and between

                          Unigene Laboratories, Inc.

                                      and

                        SmithKline Beecham Corporation
<PAGE>

                               TABLE OF CONTENTS
                               -----------------

<TABLE>
<CAPTION>
                                                                           Page
                                                                           ----
<S>                                                                        <C>
Recitals                                                                      1

ARTICLE 1    Definitions                                                      1

ARTICLE 2    License Grants                                                   8

ARTICLE 3    Payments                                                         9

ARTICLE 4    Development and Commercialization                               18

ARTICLE 5    Supply and Manufacture                                          20

ARTICLE 6    Intellectual Property                                           20

ARTICLE 7    Representations and Warranties                                  26

ARTICLE 8    Confidentiality and Exchange Of Information                     28

ARTICLE 9    Indemnification                                                 30

ARTICLE 10   Term and Termination                                            31

ARTICLE 11   Miscellaneous                                                   36

APPENDIX A   Unigene Patent Rights.........................................  40
APPENDIX B   Work Plan of Unigene Activities and FTE Requirements..........  50
APPENDIX C   Unigene Know-How and Technology Transfer......................  51
APPENDIX D   Encumbrances to Licensed Technology as of Effective Date......  53
</TABLE>

                                       i
<PAGE>

                               LICENSE AGREEMENT
                               -----------------

     This License Agreement (the "Agreement"), dated April 13, 2002 is made by
and between SmithKline Beecham Corporation, a GlaxoSmithKline company ("GSK"), a
Pennsylvania corporation, and Unigene Laboratories, Inc. ("Unigene"), a Delaware
corporation (each a "Party" and collectively, the "Parties").

                                R E C I T A L S
                                ---------------

     WHEREAS, Unigene has developed certain proprietary technology related to
     -------
oral PTH (as defined below); and

     WHEREAS, Unigene is the owner of all right, title and interest in, or
otherwise controls, certain Unigene Patent Rights (as defined below) and Unigene
Know-How (as defined below) relating to pharmaceutical compositions for oral
delivery of an active PTH peptide and the manufacture thereof; and

     WHEREAS, Unigene desires to grant to GSK, and GSK desires to obtain, an
exclusive license throughout the world under this Agreement to discover,
develop, make, have made, market, sell and import certain Licensed Products (as
defined below) throughout the world under the aforesaid Unigene Patent Rights
and Unigene Know-How;

     NOW, THEREFORE, in consideration of the mutual covenants set forth in this
Agreement, GSK and Unigene hereby agree as follows:

                                   ARTICLE 1
                                  DEFINITIONS

     1.1. "Acceptance" of an IND, NDA, or MAA or equivalent means the date of
           ----------
receipt by GSK of notice of acceptance from the FDA (or its equivalent in a
country outside the U.S.) of an IND, NDA, or MAA for a Licensed Product for
substantive review.

     1.2. "Affiliate" means any legal entity (such as a corporation,
           ---------
partnership, or limited liability company) that Controls, is Controlled by or is
under common Control with a Party to this Agreement. For the purposes of this
definition, the term "Control" means: (i) beneficial ownership of at least fifty
percent (50%) of the voting securities of a corporation or other business
organization with voting securities (or such lesser percentage which is the
maximum allowed by a foreign corporation in a particular jurisdiction); (ii) a
fifty percent (50%) or greater interest in the net assets or profits of a
partnership or other business organization without voting securities; or (iii)
the ability to direct the affairs of any such entity.

     1.3. "API" or "Active Pharmaceutical Ingredient" means PTH, in bulk active
           ---      --------------------------------
ingredient form meeting the specifications agreed to by the Parties pursuant to
Article 5.
<PAGE>

           **Certain information on this page has been omitted and filed
           separately with the Commission. Confidential treatment has been
           requested with respect to the omitted portions.

     1.4.  "** Patent" means US Patent **.
            ---------

     1.5.  "Approval" of an NDA in the United States means the FDA's approval of
            --------
an NDA filed by or on behalf of GSK under this Agreement for marketing Licensed
Product in the United States. With respect to an MAA, Approval means the
approval by all appropriate regulatory authorities of an MAA filed by or on
behalf of GSK under this Agreement for a Licensed Product, (i) with respect to
Europe, by the European Union, or other central authority; or in at least three
(3) of the European Major Markets; and (ii) with respect to Japan, in Japan.

     1.6.  "Calendar Quarter" means a three (3) month period ending on March 31,
            ----------------
June 30, September 30 or December 31.

     1.7.  "Commencement of Phase I Clinical Studies" means the date the first
            ----------------------------------------
patient is enrolled by or on behalf of GSK in the first Phase I clinical trial
for a Licensed Product.

     1.8.  "Commencement of Phase II Clinical Studies" means the date the first
            -----------------------------------------
patient is enrolled by or on behalf of GSK in the first Phase II clinical trial
for a Licensed Product.

     1.9.  "Commencement of Phase III Clinical Studies" means the date the first
            -------------------------------------------
patient is enrolled by or on behalf of GSK in the first Phase III clinical trial
for a Licensed Product.

     1.10. Confidential Information" means (i) any proprietary or confidential
           ------------------------
information or material in tangible form disclosed hereunder that is marked as
"Confidential" at the time it is delivered to the receiving Party, (ii)
proprietary or confidential information disclosed orally hereunder which is
identified as confidential or proprietary when disclosed and such disclosure of
confidential information is confirmed in writing within a reasonable period of
time thereafter by the disclosing Party, and/or (iii) any information or
material subject to an obligation of confidentiality pursuant to that certain
Confidential Disclosure Agreement entered into by the Parties as of October 18,
2001.

     1.11. "Control," "Controls," "Controlled," or "Controlling" means (except
            -------    --------    -----------      -----------
with respect to "Affiliate" as defined in Section 1.2) possession of the ability
to grant the licenses or sublicenses as provided herein without violating the
terms of any license agreement or other arrangement with any Third Party, or any
government regulation or statute.

     1.12. "Cost of Goods" means the fully allocated cost of manufacturing API
            -------------
which shall comprise all direct costs (including but not limited to labor,
materials, energy, utilities, quality control or other costs incurred directly
in the manufacture of API) and normal production overhead (including but not
limited to direct administrative labor costs, applicable manufacturing facility
and equipment maintenance, relevant insurances, and applicable depreciation of
manufacturing equipment and manufacturing facility,) specifically allocable to
the production of such API, excluding (i) any royalties owed to Third Parties
and (ii) payments provided to Unigene for FTE manufacturing resources in
accordance with Section 3.10. Cost of Goods shall be determined in accordance
with US generally accepted accounting principles.

                                       2
<PAGE>

           **Certain information on this page has been omitted and filed
           separately with the Commission. Confidential treatment has been
           requested with respect to the omitted portions.

     1.13. "Effective Date" means the date on which this Agreement was executed
            --------------
by both Parties, as set forth above.

     1.14. "European Major Markets" means France, Germany, Italy, Spain, and the
            ----------------------
United Kingdom.

     1.15. "Equivalent Product" means, as it pertains to a particular Licensed
            ------------------
Product for which there are NET SALES, a product that contains an oral
formulation of PTH where such formulation is **.

     1.16. "Field" means the use of the Licensed Product for the prophylactic
            -----
and/or therapeutic treatment of human diseases including, but not limited to,
osteoporosis.

     1.17. "FDA" means, with respect to the United States, the United States
            ---
Food and Drug Administration, any successor entity thereto, or any equivalent
foreign regulatory authority(ies) in the particular country of the Territory.

     1.18. "First Commercial Sale" means the first sale of Licensed Product to a
            ---------------------
Third Party by GSK or its Affiliate or sublicensee in a country in the
Territory.

     1.19. "Full-Time Equivalent" or "FTE" means the effort equivalent to one
            --------------------      ---
(1) full-time employee of Unigene working on a specific project or task assigned
under this Agreement, who, in Unigene's determination, is qualified to perform
such work, based on a total of ** (**) hours of work per year.

     1.20. "GSK Patent Rights" means: (i) all patents and patent applications
            -----------------
arising from work conducted by GSK in the course of conducting its activities
under this Agreement during the Term of this Agreement claiming generically or
specifically the manufacture, use or sale of PTH, API, or Licensed Product,
including, without limitation, a process for manufacturing PTH, API, or Licensed
Product, or an intermediate used in such process or a use of PTH, API, or
Licensed Product; and (ii) any divisions, continuations, continuations-in-part,
reissues, reexaminations, patents of additions, extensions or other governmental
actions which extend any of the subject matter of the patent applications or
patents in clause (i) above, and any substitutions, confirmations, registrations
or revalidations of any of the foregoing, in each case which is owned or
Controlled, in whole or part, by license, assignment or otherwise by GSK during
the Term of the Agreement, to the extent GSK has the right to license or
sublicense such GSK Patent Rights, and also to the extent to which they do not
pertain to any active component of Licensed Product other than PTH or API, and
subject to any limitations of any such license or sublicense. For the avoidance
of doubt, GSK Patent Rights shall include GSK Inventions (as defined in Section
6.1.1) and Dependent GSK Improvements (as defined in Section 6.2.1), but shall
not include Joint Patent Rights.

     1.21. "GSK Know-How" means all ideas, inventions, data, instructions,
            ------------
processes, formulas, expert opinions and information, including, without
limitation, biological, chemical,

                                       3
<PAGE>

           **Certain information on this page has been omitted and filed
           separately with the Commission. Confidential treatment has been
           requested with respect to the omitted portions.

pharmacological, physical and analytical, clinical, safety, manufacturing and
quality control data and information arising from work conducted by GSK in the
course of performing its activities under this Agreement, in each case, which
are necessary or useful for the development, testing, use, manufacture or sale
of PTH, API, or Licensed Product, to the extent to which they do not pertain to
any active component of Licensed Product other than PTH or API, and which are in
the possession of and owned or Controlled by GSK. GSK Know-How does not include
(i) know-how related to mammalian cell culture or (ii) any GSK Inventions for so
long as such are included in the GSK Patent Rights. For the avoidance of doubt,
GSK Know-How shall include GSK Inventions (as defined in Section 6.1.1) and
Dependent GSK Improvements (as defined in Section 6.2.1). GSK Know-How shall be
Confidential Information of GSK as defined in Section 1.10.

     1.22. "IND" means an investigational new drug application filed with the
            ---
FDA prior to beginning clinical trials in humans or any comparable application
filed with the regulatory authorities of a country other than the United States,
prior to beginning clinical trials in humans in that country; provided, however,
that for purposes of this definition, an IND shall not include an
investigational new drug application regarding the testing of several closely
related compounds to aid in the selection of a lead compound for further human
clinical development.

     1.23. "Joint Patent Rights" means (i) all patents and patent applications
            -------------------
arising from Joint Inventions (as defined in Section 6.1.1), and (ii) and
divisions, continuations, continuations-in-part, reissues, reexaminations,
patents of additions, extensions or other governmental actions which extend any
of the subject matter of the patent applications or patents in clause (i) above,
and any substitutions, confirmations, registrations or revalidations of any of
the foregoing.

     1.24. "Licensed Product" means a drug product in finished pharmaceutical
            ----------------
form, in any formulation containing or incorporating PTH, alone or in
combination with any pharmacologically active ingredient which is a non-peptide
or non-peptidomimetic or proprietary GSK peptide, which product incorporates
Unigene Know-How and/or is covered by Unigene Patent Rights and/or Joint Patent
Rights; provided, that, in GSK's discretion, it may request that the Parties
enter into good faith negotiations regarding the grant of rights to GSK under
Licensed Technology to commercialize a drug product in a formulation containing
or incorporating PTH in combination with a peptide or peptidomimetic compound
that is not proprietary to GSK, and, in the event Unigene has not granted, or is
not presently in discussions regarding the grant of such rights to a Third
Party, the Parties shall enter into such negotiations.

     1.25. "Licensed Technology" means Unigene Know-How and Unigene Patent
            -------------------
Rights and Joint Patent Rights. For avoidance of doubt, Licensed Technology
shall include ** IP and ** Patent.

     1.26. "MAA Pricing Approval" means with respect to a Licensed Product in a
            --------------------
country, any requisite pricing and reimbursement approval by the appropriate
regulatory authorities, such approval being at a level which is acceptable to
GSK with respect to commercial return such that it is commercially reasonable
for GSK to launch Licensed Product.

                                       4
<PAGE>

           **Certain information on this page has been omitted and filed
           separately with the Commission. Confidential treatment has been
           requested with respect to the omitted portions.

     1.27. "Marketing Approval Application" or "MAA" means a filing for
            ---------------------------------------
marketing approval (not including pricing or reimbursement approval) in a
country other than the United States, in each case with respect to a Licensed
Product in the Territory.

     1.28. "Marketing Authorization" means an MAA and/or NDA.
            -----------------------

     1.29. "Net Sales" means the gross amount billed or invoiced on sales by
            ---------
GSK, its Affiliates and sublicensees of Licensed Product (the "Selling Party"),
less the following:

     (i)   customary trade, quantity, and cash discounts or rebates actually
           allowed on Licensed Product;

     (ii)  credits or allowances given to customers for rejections or returns of
           Licensed Product or on account of retroactive price reductions
           affecting such Licensed Product;

     (iii) sales and excise taxes and duties paid or allowed by the Selling
           Party and any other governmental charges levied on the production,
           importation, use or sale of a Licensed Product;

     (iv)  transportation charges to the extent that they are included in the
           price or otherwise paid by the purchaser, including insurance, for
           transporting Licensed Product; and

     (v)   Licensed Product rebates and Licensed Product chargebacks including
           those granted to managed-care entities and government agencies; and

     (vi)  ** percent (**%) of the sum of gross sales less the amounts set forth
           in clauses (i) through (v) above to reflect the actual uncollectable
           accounts.

Sales or transfers of Licensed Products among GSK, an Affiliate and/or a
sublicensee shall be excluded from the computation of Net Sales, and no
royalties will be payable on such sales.

     1.30. "NDA" means, with respect to the United States, a New Drug
            ---
Application (as defined in 21 C.F.R. (S) 314.50 et. seq. or any successor
regulations), and all subsequent supplements to that NDA.

     1.31. "**" means ** a corporation with offices at **.
            --

     1.32. "**" means ** Patent **, ** Patent No. **, and any other patent
            --
and/or patent applications, including any future divisionals, continuations,
continuations-in-part, reissues and reexaminations, licensed to Unigene pursuant
to the **License Agreement.

                                       5
<PAGE>

           **Certain information on this page has been omitted and filed
           separately with the Commission. Confidential treatment has been
           requested with respect to the omitted portions.

     1.33. "** License Agreement" means the license agreement between Unigene
            --------------------
and ** relating to the ** IP, **.

     1.34. "Phase I" means Phase I clinical trials, as prescribed by applicable
            -------
FDA regulations.

     1.35. "Phase II" means Phase II clinical trials, as prescribed by
            --------
applicable FDA regulations.

     1.36. "Phase III" means Phase III clinical trials, as prescribed by
            ---------
applicable FDA regulations.

     1.37. "PTH" means all forms of parathyroid hormone and any and all
            ---
formulations thereof (including, but not limited to truncates, fusion proteins,
muteins and chemical modifications of any or all of the aforementioned).

     1.38. "Similar Product" means, as it pertains to a particular Licensed
            ---------------
Product for which there are Net Sales, a product that contains an oral
formulation of PTH which is **.

     1.39. "Term" means the term of this Agreement as set forth in Section 10.1.
            ----

     1.40. "Territory" means all the countries and territories of the world;
            ---------
provided that, should this Agreement expire as to any country or territory
pursuant to Section 10.1, or should GSK terminate this Agreement as to any
country or territory pursuant to Section 10.4, such country or territory shall
no longer be considered within the Territory. As used in this Agreement,
"country" shall refer to country or territory, as appropriate.

     1.41. "Third Party(ies)" means any party(ies) other than Unigene, GSK, or
            ----------------
an Affiliate of either of them.

     1.42. "Unigene Formulation Patent Rights" means: (i) all patents and patent
            ---------------------------------
applications in existence as of the Effective Date or arising during the Term of
this Agreement claiming generically or specifically the formulation of PTH; and
(ii) any divisions, continuations, continuations-in-part, reissues,
reexaminations, patents of additions, extensions or other governmental actions
which extend any of the subject matter of the patent applications or patents in
clause (i) above, and any substitutions, confirmations, registrations or
revalidations of any of the foregoing, in each case which is owned or
Controlled, in whole or part, by license, assignment or otherwise by Unigene as
of the Effective Date or during the TERM of the Agreement, to the extent Unigene
has the right to license or sublicense such Unigene Formulation Patent Rights,
and subject to any limitations of any such license or sublicense. The current
list of patent applications and patents encompassed within Unigene Formulation

                                       6
<PAGE>

           **Certain information on this page has been omitted and filed
           separately with the Commission. Confidential treatment has been
           requested with respect to the omitted portions.

Patent Rights is set forth in Appendix A to this Agreement, attached hereto and
incorporated herein. Appendix A shall be updated on a semi-annual basis during
the Term of the Agreement. For the avoidance of doubt, Unigene Formulation
Patent Rights shall include Unigene Inventions (as defined in Section 6.1.1) and
**IP.

     1.43. "Unigene General Patent Rights" means: (i) all patents and patent
            -----------------------------
applications in existence as of the Effective Date or during the Term of this
Agreement claiming generically or specifically the manufacture, use or sale of
PTH, API or Licensed Product including, without limitation, a process for
manufacturing PTH, API or Licensed Product, or an intermediate used in such
process or a use of PTH, API or Licensed Product; and (ii) any divisions,
continuations, continuations-in-part, reissues, reexaminations, patents of
additions, extensions or other governmental actions which extend any of the
subject matter of the patent applications or patents in clause (i) above, and
any substitutions, confirmations, registrations or revalidations of any of the
foregoing, in each case which is owned or Controlled, in whole or part, by
license, assignment or otherwise by Unigene as of the Effective Date or during
the Term of the Agreement, to the extent Unigene has the right to license or
sublicense such Unigene General Patent Rights, and subject to any limitations of
any such license or sublicense. The current list of patent applications and
patents encompassed within Unigene General Patent Rights is set forth in
Appendix A. Appendix A shall be updated by Unigene on a semi-annual basis during
the Term of the Agreement. For the avoidance of doubt, Unigene General Patent
Rights shall include Unigene Inventions (as defined in Section 6.1.1) and the **
Patent (as defined below).

     1.44. "Unigene Know-How" means all ideas, inventions, data, instructions,
            ----------------
processes, formulas, expert opinions and information, including, without
limitation, biological, chemical, pharmacological, physical and analytical,
clinical, safety, manufacturing and quality control data and information, in
each case, which are necessary or useful for the development, testing, use,
manufacture or sale of API, PTH or Licensed Product and which is in the
possession of and owned or Controlled by Unigene. Unigene Know-How does not
include any Unigene Inventions for so long as such are included in the Unigene
Patent Rights. For avoidance of doubt, Unigene Know-How shall include Unigene
Inventions (as defined in Section 6.1.1). Unigene Know-How shall be Confidential
Information of Unigene as defined in Section 1.10.

     1.45. "Unigene Patent Rights" means Unigene Formulation Patent Rights and
            ---------------------
Unigene General Patent Rights.

     1.46. "** Patent" means U.S. Patent No. **.
            ---------

     1.47. "** Patent License Agreement" means the license agreement between
            ---------------------------
Unigene and the ** relating to the ** Patent, **.

     1.48. "Valid Claim" means either: (i) a claim of an issued patent within
            -----------
Unigene Formulation Patent Rights that has not been held unenforceable or
invalid by an agency or a court of competent jurisdiction in any unappealable or
unappealed decision or (ii) a claim of a

                                       7
<PAGE>

pending patent application within Unigene Formulation Patent Rights that has not
been outstanding for more than three (3) years, nor abandoned or finally
rejected without the possibility of appeal or refiling.

     1.49. "Work Plan" means the plan, as described in Section 4.2, and as set
            ---------
forth in Appendix B to this Agreement, attached hereto and incorporated herein.

                                   ARTICLE 2
                                LICENSE GRANTS

     2.1.  License Grant from Unigene to GSK.
           ---------------------------------

           2.1.1.  Subject to the terms and conditions of this Agreement,
Unigene hereby grants to GSK (i) an exclusive license, even as to Unigene, under
the Licensed Technology, to make, have made, use, sell, offer for sale and
import Licensed Product in the Territory in the Field and (ii) an exclusive
license, even as to Unigene, under the Licensed Technology, to make, have made,
use, and import API and PTH in the Territory. These licenses include the right
to sublicense as to using, selling, offering for sale and importing Licensed
Product, the right to sublicense as to using and importing API and PTH and,
subject to Section 2.1.2, the right to sublicense as to making and having made
API, PTH and Licensed Product.

           2.1.2.  (a)  GSK has the right to sublicense all aspects of secondary
manufacture of Licensed Product (i.e., the manufacture of Licensed Product other
than manufacture of API and PTH) without further consent or approval of Unigene;

                   (b)  If, during the Term, GSK elects not to manufacture API
or PTH itself for Licensed Product, and the Parties do not agree to a supply
agreement pursuant to Section 5.2, GSK may select a Third Party manufacturer to
produce API and/or PTH required by GSK; provided, however, that prior to
contracting with a Third Party manufacturer to produce API and/or PTH, GSK shall
consult with Unigene to ensure that the Third Party manufacturer is acceptable
to Unigene, and Unigene shall not unreasonably withhold or delay its consent to
the retention by GSK of the THIRD PARTY manufacturer. Should GSK contract with a
Third Party for the manufacture of API and/or PTH pursuant to this Section, GSK
shall ensure that such Third Party agrees to keep confidential any Unigene Know-
How provided to it, under confidentiality provisions no less stringent than
those applicable to Unigene and GSK under Article 8.

           2.1.3.  Notwithstanding the grant of exclusive license to GSK in
Sections 2.1.1 and 2.1.2, Unigene shall have the right to manufacture PTH for a
Third Party or for GSK in accordance with Article 5, but only to the extent that
(i) such PTH is not the identical PTH molecule as is then being developed and/or
commercialized by GSK anywhere in the Territory in the Field; and (ii) Unigene
has obtained a binding contractual commitment of the Third Party that such PTH
shall not be used by the Third Party or any of its partners, agents, licensees
for oral delivery of PTH in the Field in the Territory. Any contract that
Unigene

                                       8
<PAGE>

           **Certain information on this page has been omitted and filed
           separately with the Commission. Confidential treatment has been
           requested with respect to the omitted portions.

enters into with a Third Party shall include the right of GSK to enforce such
contract on behalf of Unigene against the Third Party.

     2.2.  Sublicense of **IP. Upon the effective date of the ** License
           ------------------
Agreement, Unigene exclusively sublicenses to GSK its rights under the **
License Agreement. In exchange for such sublicense, upon Unigene's written
request, GSK shall promptly pay to ** the license fees and milestones due and
owing under the ** License Agreement to the extent set forth in Section 3.7.

     2.3.  ** Patent License Agreement. Upon the effective date of the ** Patent
           ---------------------------
License Agreement, the ** Patent shall become part of Unigene Patent Rights.
Unigene shall remain obligated for any and all license fees and milestones due
and owing under the ** Patent License Agreement.

     2.4.  License Grant from GSK to Unigene on Termination. In the event of
           ------------------------------------------------
termination by GSK under Section 10.4, or termination by Unigene under Section
10.2 or 10.3, and in accordance with Section 10.5.4, upon such termination, GSK
grants to Unigene the following license:

           (a)  an exclusive, world-wide, royalty-free, irrevocable, perpetual
license, with the right to grant sublicenses, under GSK Patent Rights, GSK Know-
How, Joint Patent Rights and Joint Inventions (other than GSK Inventions and
Joint Inventions licensed to Unigene pursuant to Section 6.2), solely to make,
have made, use, sell, offer for sale and import an oral PTH product;

           (b)  the license granted to Unigene under this Section 2.4 shall not
include any license to develop or commercialize any drug product which does not
include PTH, and any such license from GSK to Unigene for such drug product
under GSK Patent Rights, GSK Know-How, Joint Patent Rights and Joint Inventions
(other than GSK Inventions and Joint Inventions licensed to Unigene pursuant to
Section 6.2) shall be subject to good faith negotiation between the Parties,
which negotiation may result in a grant of such license if GSK is not pursuing
development of commercialization of such drug product itself or with another
company.

                                   ARTICLE 3
                                   PAYMENTS

     3.1.  Initial Fee to Unigene. In partial consideration for the license to
           ----------------------
Licensed Technology granted to GSK under Section 2.1 of this Agreement, GSK
shall pay to Unigene two million U.S. dollars (U.S. $2,000,000) within ** (**)
business days after the Effective Date, which amount shall be non-refundable and
not creditable against other amounts due Unigene under this Agreement.

     3.2.  Milestone Payments to Unigene.
           -----------------------------

                                       9
<PAGE>

           **Certain information on this page has been omitted and filed
           separately with the Commission. Confidential treatment has been
           requested with respect to the omitted portions.

     (a) Licensed Product.  In partial consideration for the license to Licensed
         ----------------
Technology granted to GSK under Section 2.1 of this Agreement, GSK shall pay
Unigene the following amounts following the first achievement by Unigene, GSK,
its Affiliates or sublicensees, as applicable, as the case may be, of each of
the following milestones with respect to the Licensed Product ("Milestones"):

      Milestone                                                     Amounts
      ---------                                                     -------
 1   **                                                             U.S. $**
 2.  **                                                             U.S. $**
 3.  **                                                             U.S. $**
 4.  **                                                             U.S. $**
 5.  **                                                             U.S. $**
 6.  **                                                             U.S. $**
 7.  **                                                             U.S. $**
 8.  **                                                             U.S. $**
 9.  **                                                             U.S. $**
10.  **                                                             U.S. $**
11.  **                                                             U.S. $**
12.  **                                                             U.S. $**

                                      10
<PAGE>

          ** Certain information on this page has been omitted and filed
          separately with the Commission. Confidential treatment has been
          requested with respect to the omitted portions.

13.  **                                                         U.S. $**
14.  **                                                         U.S. $**
15.  **                                                         U.S. $**
16.  **                                                         U.S. $**
17.  **                                                         U.S. $**

provided that:

          (1)  GSK shall provide written notice of achievement of a Milestone to
Unigene within ** (**) business days after such event. Unigene shall provide an
invoice to GSK within ** (**) business days of receipt of the notification.
Notwithstanding the foregoing, as to Milestones 1 and 2, Unigene shall provide
an invoice to GSK upon achievement of such Milestones. GSK shall pay Unigene the
Milestone amount within ** (**) business days of receipt of an invoice from
Unigene;

          (2)  each such payment shall be made only one time, based upon the
first Licensed Product to achieve a particular Milestone, regardless of how many
times such Milestone is achieved, and Milestone 4 shall be paid only after
Milestone 3 has been achieved and paid;

          (3)  payment shall not be owed for a Milestone that is not achieved,
provided that (a) upon the achievement of any of Milestones 5 - 7, all prior
Milestones are deemed achieved as of that date, and payments for such prior
Milestones are due and owing according to this Section 3.2, and (b) as to
Milestones, 1,2, and 8 - 17, the Milestones may be achieved in any order, and
achievement of any Milestone shall be subject to payment under this Section 3.2
whenever achieved;

          (4)  each such payment shall be non-refundable and non-creditable to
GSK against other amounts due to Unigene under this Agreement; and

          (5)  the achievement of "**", "**" and "**" as used in this Section
3.2 shall be determined by criteria established by the JDC (as defined in
Section 4.3), but, in any case, should the JDC decide to progress toward **
(Milestone 5), if either of Milestone 3 and Milestone 4 has not yet been
achieved, it shall be deemed achieved as of the

                                       11
<PAGE>

          ** Certain information on this page has been omitted and filed
          separately with the Commission. Confidential treatment has been
          requested with respect to the omitted portions.

date of the achievement of Milestone 5, and payment for either or both such
Milestones, if not previously made, shall be due and owing according to this
Section 3.2;

          (6)  "annual worldwide Net Sales" as used in this Section shall mean
the aggregate Net Sales for all Licensed Product in a calendar year across all
countries in the Territory.

     3.3. Second Generation Licensed Product.  In partial consideration for the
          ----------------------------------
License to Licensed Technology granted to GSK under Section 2.1 of this
Agreement, should GSK, in its sole discretion and at its option, undertake
development of a second generation Licensed Product and achieve ** for such
second generation Licensed Product, GSK shall pay to Unigene ** U.S. dollars
(U.S.$**), which amount shall be non-refundable and not creditable against other
amounts due Unigene under this Agreement. For purposes of this Section 3.3,
"second generation Licensed Product" shall mean a Licensed Product which enters
Phase I after First Commercial Sale of a different Licensed Product. GSK shall
provide written notice to Unigene immediately upon such **, and pay Unigene
within ** (**) days of receipt of an invoice. Except for the fee set forth in
this Section 3.3, there shall be no other milestone payments for each such
second generation Licensed Product.

     3.4. Unigene Formulation Patent Rights Royalties.
          -------------------------------------------

          3.4.1. Royalties on Net Sales where Valid Claim of Unigene Formulation
                 ---------------------------------------------------------------
Patent Rights Exists.  In partial consideration of the license and rights
--------------------
granted under Unigene Formulation Patent Rights hereunder, GSK shall pay
royalties to Unigene on Net Sales of all Licensed Products covered by a Valid
Claim of Unigene Formulation Patent Rights as follows:

          (a)    ** percent (**%) of annual Net Sales up to ** U.S. dollars
(*U.S. $**);

          (b)    ** percent (**%) of annual Net Sales including and in excess of
** U.S. dollars (***US $**) up to ** U.S. dollars (*U.S. $**);

          (c)    ** percent (**%) of annual Net Sales including and in excess of
** U.S. dollars (***U.S. $**) up to ** U.S. dollars (*U.S. $**); and

          (d)    ** percent (**%) of annual Net Sales including and in excess of
** U.S. dollars (***U.S. $**);

provided that, for purposes of this Section, achievement of the Net Sales
thresholds set forth shall be determined by adding the total annual Net Sales of
all Licensed ProductS during each calendar year in all countries of the
Territory in which there is a Valid Claim of Unigene

*   means less than
*** means more than or equal to

                                       12
<PAGE>

          ** Certain information on this page has been omitted and filed
          separately with the Commission. Confidential treatment has been
          requested with respect to the omitted portions.

Formulation Patent Rights claiming the particular Licensed Product at the time
such Net Sales of such Licensed Product occur.

By way of example, if the annual Net Sales were ** U.S. dollars (U.S. $**), then
the royalties due under this Section would be ** U.S. dollars (U.S. $**),
calculated as (U.S. $** x **%) plus (U.S. $** x **%).

          3.4.2. Payment of Royalties.  Payment of royalties shall be made
                 --------------------
forty-five (45) days after the end of each Calendar Quarter on all Net Sales in
the preceding quarter ("Quarterly Payment"). Each Quarterly Payment shall be
accompanied by a report detailing the total Net Sales by country in the
Territory for the preceding Calendar Quarter, and, if GSK is claiming a reduced
royalty rate under Section 3.4.3 or 3.4.4, the sales volume of the Equivalent
Product or Similar Product, as measured by IMS or an equivalent Third Party
service acceptable to both Parties. In the event that a Net Sales threshold as
described in Section 3.4.1 is met during a Calendar Quarter, all subsequent
Quarterly Payments in that calendar year shall be made at the higher applicable
royalty rate. Included in the Quarterly Payment for the fourth Calendar Quarter
of each calendar year, GSK shall include any additional royalties owed for Net
Sales in the calendar year to which the last Calendar Quarter relates, based on
the annual Net Sales.

          3.4.3. Royalty where Substantial Competition of an Equivalent Product
                 --------------------------------------------------------------
Exists.  Where substantial competition by an Equivalent Product exists in a
------
country in which a Valid Claim within all Unigene Formulation Patent Rights
exists, the applicable royalties set forth in Section 3.4.1 on Net Sales in such
country shall be reduced by ** percent (**%) for each Calendar Quarter in which
substantial competition exists. By the term "substantial competition" as used in
this Section 3.4.3 is meant the situation where an Equivalent Product achieves
** percent (**%) or more sales (by volume) of the Licensed Product, in such
country, as measured by IMS or an equivalent Third Party service acceptable to
both Parties, on a monthly basis for each month of a Calendar Quarter.

          3.4.4. Royalty where Substantial Competition of a Similar Product
                 ----------------------------------------------------------
Exists. In the event Section 3.4.3 does not apply, where substantial competition
------
by a Similar Product exists in a country in which a Valid Claim within the
Unigene Formulation Patent Rights exists, the applicable royalties set forth in
Section 3.4.1 on Net Sales in such country shall be reduced by ** percent (**%)
for each Calendar Quarter in which substantial competition exists.  By the term
"substantial competition" as used in this Section 3.4.4 is meant the situation
where a Similar Product achieves ** percent (**%) or more sales (by volume) of
the Licensed Product in such country, as measured by IMS or an equivalent Third
Party service acceptable to both Parties, on a monthly basis for each month of a
Calendar Quarter.

          3.4.5. Single Royalty; Non-Royalty Sales.  No royalty shall be payable
                 ---------------------------------
under Section 3.4.1 above with respect to sales of the Licensed Product among
GSK, its Affiliates and sublicensees for resale to a Third Party. In no event
shall more than one such royalty be due Unigene hereunder with respect to the
sale of each Licensed Product, even if such Licensed

                                       13
<PAGE>

          ** Certain information on this page has been omitted and filed
          separately with the Commission. Confidential treatment has been
          requested with respect to the omitted portions.

Product is covered by more than one Valid Claim within the Unigene Formulation
Patent Rights.

     3.5. Royalties on Net Sales where No Valid Claim of Unigene Formulation
          ------------------------------------------------------------------
Patent Rights Exists.  In the event that no royalty on certain Net Sales is paid
--------------------
under Section 3.4, as further consideration for the licenses granted to GSK
under Section 2.1 of this Agreement, GSK shall pay to Unigene ** percent (**%)
of the otherwise applicable royalty rate set forth in Section 3.4.1 on such Net
Sales. Where substantial competition exists in such Country where there is no
Valid Claim, the royalty rate outlined in Section 3.4 on Net Sales in such
country shall be reduced by ** percent (**%) for each Calendar Quarter in which
substantial competition exists. By the term "substantial competition" as used in
this Section 3.5 is meant the situation where an Equivalent Product achieves **
percent (**%), or Similar Product achieves ** percent (**%) or more sales (by
volume) of the Licensed Product, in such country, as measured by IMS or an
equivalent Third Party service acceptable to both Parties, on a monthly basis
for each month of the Calendar Quarter.

     3.6. Royalty Term.  The obligation of GSK to pay royalties under Section
          ------------
3.4 shall continue for each Licensed Product on a Licensed Product-by-Licensed
Product and country-by-country basis, until such time as there are no Valid
ClaimS of Unigene Formulation Patent Rights covering the manufacture, sale or
use of such Licensed Product in such country. The obligation of GSK to pay
royalties under Section 3.5 shall continue for each Licensed Product on a
Licensed Product-by-Licensed Product basis and country-by-country basis until **
(**) years from the date of First Commercial Sale of such Licensed Product in
such country. In the event that the obligation of GSK to pay royalties under
Section 3.4.1 as to a Licensed Product expires prior to ** (**) years from the
date of First Commercial Sale of such Licensed Product, upon such expiration,
GSK shall be obliged to pay royalties under Section 3.5 as to such Licensed
Product.

     3.7. ** License Fees and Milestones.  In accordance with Unigene's sub-
          ------------------------------
license to GSK of the ** License Agreement, GSK shall be fully responsible for
the prompt payment to **, upon Unigene's prompt notice and request, of those
certain license fees and milestones due from Unigene to ** under the ** License
Agreement and specified below, not to exceed the amounts set forth below:

                                   Milestone                          Amounts
                                   ---------                          -------

1. **                                                                 U.S. $**
2. **                                                                 U.S. $**

                                       14
<PAGE>

          ** Certain information on this page has been omitted and filed
          separately with the Commission. Confidential treatment has been
          requested with respect to the omitted portions.

3. **                                                              U.S. $**
4. **                                                              U.S. $**
5. **                                                              U.S. $**
6. **                                                              U.S. $**

provided that:

          (1)  each such payment shall be made only one time to ** by GSK based
upon the first Licensed Product to achieve a particular Milestone regardless of
how many times such Milestone is achieved;

          (2)  the Milestone 2 payment shall not be made in the event Milestone
3 occurs prior to Milestone 2;

          (3)  payment shall not be owed for a Milestone that is not reached;
and

          (4)  as to Milestone 4, the option to pay the Milestone on successful
** or ** shall be as specified in the ** License Agreement.

GSK shall pay the above amounts to ** upon Unigene's notice and request and in
accordance with the ** License Agreement; provided, however, that in the event
that GSK fails to remit such payment to ** in a timely fashion after receiving
notice from Unigene that payment to ** is due from GSK, Unigene shall be
entitled to remit payment directly to **.  In such event, Unigene shall be
entitled to seek reimbursement from GSK of any amounts paid to **,  or, at
Unigene's option, to deduct any such payments from future payments due GSK under
this Agreement.  Other than as set forth above, Unigene shall be fully
responsible for any other royalties, license fees, Milestones and any and all
other payments due from Unigene to ** or any other entity under the ** License
Agreement.

     3.8. Third Party Fees or Royalties.  GSK shall be fully responsible for the
          -----------------------------
payment of any additional royalties, license fees, milestones and any and all
other payments due to Third Parties other than those due under the ** License
Agreement or in relation to the ** Patent that are required for GSK or its
licensees to develop, manufacture, use, market, sell or

                                       15
<PAGE>

          ** Certain information on this page has been omitted and filed
          separately with the Commission. Confidential treatment has been
          requested with respect to the omitted portions.

import PTH or Licensed Product, until First Commercial Sale of Licensed Product.
After First Commercial Sale, Unigene shall be responsible for ** percent (**%)
of royalties due Third Parties which are directly related to GSK or its
licensees' manufacture, use, sale or import of Licensed Technology, at GSK's
request and upon provision of sufficient documentation by GSK to show the
existence of such an obligation and its direct relation to the Licensed
Technology. Unigene shall meet its responsibility for such payments solely in
the form of deductions from Quarterly Payments, and in no event shall such
deductions exceed ** percent (**%) of any Quarterly Payment. GSK shall consult
with Unigene before entering into any agreement which might subject Unigene to
obligations under this Section 3.8; however, GSK shall retain the right of final
decision.

     3.9. Third Party Payments - ** Patent.
          --------------------------------

          3.9.1. Unigene Notification Regarding ** Patent.  Notwithstanding
                 ----------------------------------------
Unigene's obligations under Section 3.8 of this Agreement to reimburse part of
certain Third Party payments, Unigene shall have no such obligation to make any
such payments for use of technology claimed in the ** Patent in the event that:
(i) Unigene notifies GSK in writing that it believes that the method of
manufacture of the API and/or the Licensed Product is not within the scope of
any claim of the ** Patent; and (ii) GSK does not respond in writing to Unigene
within forty-five (45) days of receipt of Unigene's notice. In the event GSK
provides written response to Unigene, GSK will notify Unigene of its election to
have an outside patent expert ("Outside Expert") who is not affiliated with
either Party determine whether the method of manufacturing the API and/or the
Licensed Product is within one or more claims of the ** Patent, in accordance
with Section 3.9.2 below.

          3.9.2. Outside Expert Opinion on Scope of ** Patent.  In the event
                 --------------------------------------------
that GSK gives notice to Unigene under Section 3.9.1 that GSK elects an Outside
Expert determination, the Parties shall promptly select a mutually acceptable
objective patent expert to act as Outside Expert and shall supply such Outside
Expert with such materials and information as either Party may deem relevant, or
as the Outside Expert may request. The Outside Expert will be asked to render a
full and well reasoned, written opinion ("Opinion") that the Outside Expert
believes that it is more likely than not that either:

          (1)    the manufacturing process for the API and/or Licensed Product
is within the scope of the ** Patent; or
   ------

          (2)    the method of manufacturing the API and/or Licensed Product is
outside the scope of the ** Patent.
-------

The Outside Expert, in rendering this Opinion, shall utilize only the facts and
materials provided by the Parties and shall apply the body of law relevant to
patent claim interpretation for infringement purposes (including doctrine of
equivalents and file history estoppel analysis), as set forth in Title 35 of the
United States Code and related case law.  The Opinion shall contain the Outside
Expert's explanation for his conclusions and shall be provided to both parties
promptly after completion.

                                       16
<PAGE>

           ** Certain information on this page has been omitted and filed
           separately with the commission. Confidential treatment has been
           requested with respect to the omitted portions.

           3.9.3. Effect of Opinion.  In the event that the Outside Expert
                  -----------------
determines that the method of manufacturing the API and/or Licensed Product is
not within the scope of the ** Patent, then Unigene shall not be required to
reimburse GSK with respect to the ** Patent, and GSK shall reimburse Unigene for
all deductions from Quarterly Payments related to use of technology claimed in
the ** Patent made after the date of notice provided under Section 3.9.1, such
reimbursement to be made no later than the next Quarterly Payment after the date
of the Opinion set forth in Section 3.9.2.  In the event that the Outside Expert
determines that the method of manufacturing the API and/or the Licensed Product
is within the scope of the ** Patent, then Unigene's obligation of reimbursement
under Section 3.7 with respect to the ** Patent shall continue uninterrupted.

           3.9.4. Fees.  The fees paid to the Outside Expert shall be borne
                  ----
equally between the Parties.

           3.9.5. Finality.  The Opinion of the Outside Expert shall be final
                  --------
for the purposes of determining Unigene's reimbursement obligations under
Section 3.7 of this Agreement with respect only to the ** Patent, and shall not
be appealable by either Party. However, the procedure set forth in Section 3.9
may be repeated upon the request of either Party in the event that the method of
manufacturing the API and/or Licensed Product is substantially changed and/or
the ** Patent is reissued subsequent to the rendering of an Opinion by an
Outside Expert.

     3.10. Unigene FTE Payments.  As consideration for work conducted
           --------------------
by Unigene FTEs in accordance with the Work Plan and/or as authorized by the JDC
or Project Team, GSK shall pay Unigene ** U.S. dollars (U.S. $**) per year per
Unigene FTE, which rate shall increase each calendar year upon the anniversary
date of the Effective Date by a percentage equal to the increase in the CPI, All
Urban Consumers, in the previous calendar year, and shall reimburse Unigene for
all preapproved out-of-pocket costs and expenses (including, but not limited to,
reasonable travel and hotel costs) consistent with the Work Plan and/or as
authorized by the JDC or Project Team.  Subject to further changes in the WORK
PLAN at the mutual agreement of the Parties, the maximum payments payable to
Unigene are set forth in Appendix B.  GSK shall make payment to Unigene on a
monthly basis for work conducted by Unigene in accordance with the Work Plan
within ** (**) days of receipt of an invoice from Unigene.  Each invoice shall
describe in detail the work performed by Unigene FTEs and a breakdown of hours
of work performed.

     3.11. Currencies.  Payments under this Agreement shall be made in United
           ----------
States Dollars. Revenues and expenses for each country shall be converted into
United States Dollars using the applicable exchange rate for converting such
local currency to the United States Dollar in accordance with the exchange rates
used by GSK in producing its financial accounts at the time and detailed in its
annual report.

     3.12. Manner of Payments.  All sums due to Unigene or to ** under this
           ------------------
Agreement shall be payable in United States Dollars by bank wire transfer in
immediately available funds to such bank account as Unigene shall designate. GSK
shall notify Unigene as to

                                       17
<PAGE>

           ** Certain information on this page has been omitted and filed
           separately with the Commission. Confidential treatment has been
           requested with respect to the omitted portions.

the date and amount of any such wire transfer to Unigene at least two (2)
business days prior to such transfer.  Interest for payments that are not paid
within thirty (30) days of the date on which they were due shall accrue at **
percent (**%) per month or portion thereof from the date payment was due.

     3.13. Tax Withholding.  Any tax, duty or other levy paid or required to be
           ---------------
withheld by GSK or its sublicensees on account of royalties or other payments
payable to Unigene or ** under this Agreement shall be deducted from the amount
of royalties or payments otherwise due, provided that GSK shall make such
deductions only to the minimum extent required by the relevant jurisdiction. GSK
shall secure and send to Unigene and ** proof of any such taxes, duties or other
levies withheld and paid by GSK or its sublicensees for the benefit of Unigene
and **, and cooperate at Unigene's reasonable request to ensure that amounts
withheld are reduced to the fullest extent permitted by the relevant
jurisdiction.

     3.14. Financial Records and Audits;Unigene's Right to Audit. Unigene, at
           -----------------------------------------------------
its own cost, through an independent auditor reasonably acceptable to GSK, may
inspect and audit the records of GSK pertaining to the sale of Licensed Product
and any royalties due to Unigene under Section 3.4. GSK shall provide such
auditors with access to the records during reasonable business hours. Such
access need not be given to any such set of records more often than once each
year or more than three (3) years after the date of any report to be audited,
and the auditors shall report to Unigene only the amount of royalty due. Unigene
shall provide GSK with written notice of its election to inspect and audit the
records related to the royalty due hereunder not less than thirty (30) days
prior to the proposed date of review of GSK's records by Unigene's auditors. GSK
shall maintain sufficient records to permit the inspection and auditing
permitted hereunder for three (3) years after the date of each respective
reporting period. GSK shall prepare its records and reports according to
generally accepted accounting principles of the United States. Should the
auditor find any underpayment of royalties by GSK, GSK shall promptly pay
Unigene the amount of such underpayment, plus interest at the rate of ** percent
(**%) per month or portion thereof on the amount of any underpayment from the
date payment was due, and shall reimburse Unigene for the cost of the audit
should such underpayment equal or exceed ** percent (**%) of royalties paid
during the time period audited.

                                   ARTICLE 4
                       DEVELOPMENT AND COMMERCIALIZATION

     4.1.  Licensed Product Development by GSK.
           -----------------------------------

           4.1.1. GSK Responsibilities.  Except as expressly provided otherwise
                  --------------------
in this Agreement, GSK shall undertake  and resource all development of Licensed
Product(s) in the Field in the Territory so long as it retains full rights
thereto under this Agreement, and shall bear all costs it incurs in conducting
such development, including, without limitation, expenses incurred in conducting
clinical trials.  GSK shall be responsible, at its sole expense on a country-by-
country basis, for the commercialization and distribution of such Licensed
Product(s) in the Field in the Territory so long as GSK retains rights, on a
country-by-country basis, thereto

                                       18
<PAGE>

under this Agreement.  Subject to its obligations in Section 4.1.2, GSK shall
have the sole discretion, using its reasonable business judgment, to decide
whether to commercialize a Licensed Product in a country in the Territory.

           4.1.2. Diligent Efforts.  GSK shall commit such efforts and
                  ----------------
resources during development and commercialization of the Licensed Product
throughout the Territory at a level commensurate to those efforts and resources
committed by GSK to developing and commercializing its own compounds and
products.  Such efforts shall be no less than the level of effort and resource
standard in the pharmaceutical industry with respect to a product at a similar
state in its development or product life in the context of a similar product
portfolio.  GSK shall keep the Project Team (as defined below) and the Joint
Development Committee (as defined below), as applicable, advised of its
development and manufacturing plans and activities with respect to PTH, API and
Licensed Product.

     4.2.  Unigene Development Responsibilities.  The Work Plan which outlines
           ------------------------------------
the initial responsibilities of Unigene to assist GSK in the manufacture of API,
the transfer of Unigene Know-How, and otherwise as agreed by the Parties, is
attached hereto as Appendix B. Subject to the Work Plan being updated from time
to time upon mutual agreement of both Parties, GSK shall not be obligated to
fund any Unigene FTEs other than to the extent set forth in Appendix B.

     4.3.  The Joint Development Committee.
           -------------------------------

           4.3.1. Within sixty (60) days after the Effective Date, the Parties
shall establish a Joint Development Committee ("JDC"). The JDC shall have
responsibility to oversee, review, coordinate and expedite the development of
Licensed Product and the progress of work being conducted under the Work Plan,
and to update the Work Plan from time to time. The JDC shall be comprised of GSK
representatives and one representative from Unigene. At Unigene's discretion,
additional Unigene personnel, up to a maximum of three (3), may attend meetings
of the JDC, but only the designated Unigene representative shall vote on matters
before the JDC. The JDC shall meet quarterly, or as more or less often as
otherwise agreed by the Parties, at such locations as the Parties agree. Unigene
shall be provided with a copy of all reports to or by the JDC, including
summaries of JDC meetings at the same time that such materials are provided to
GSK members of the JDC. Any decision that cannot be made unanimously by the JDC
shall be discussed by the appropriate representatives of the Parties; provided
that, in the event of continued disagreement, or otherwise, GSK shall make all
final decisions regarding the conduct and progress of the development of
Licensed Product.

          4.3.2.  After Approval in the United States for the Licensed Product,
the members of the JDC shall continue to meet on a quarterly basis or as
necessary to oversee, review, coordinate and expedite the development and
commercialization of the Licensed Product in countries outside the United
States. GSK shall continue to have final decision making authority over the
development and commercialization of the Licensed Product in the Territory.

                                       19
<PAGE>

           ** Certain information on this page has been omitted and filed
           separately with the Commission. Confidential treatment has been
           requested with respect to the omitted portions.

     4.4.  Project Team.  Promptly after the Effective Date, GSK shall form a
           ------------
project team to coordinate the development of Licensed Product (the "Project
Team"). The Project Team will be comprised of GSK personnel and where
appropriate in GSK's reasonable judgment, Unigene personnel who are responsible
for conducting and progressing the work outlined in the Work Plan. It is
anticipated that Unigene personnel shall attend meetings of the Project Team at
which the Work Plan is discussed. Such Project Team shall meet as often as
agreed upon by the Parties and shall report to the JDC. Unigene shall be
promptly provided with a copy of all Project Team reports, including summaries
of Project Team meetings, to the extent such reports and summaries relate to the
development of the Licensed Product, which materials shall be provided to
Unigene at the same time that they are provided to GSK members of the Project
Team.

     4.5.  Unigene Data Transfer.  Immediately after the Effective Date,
           ---------------------
Unigene shall use its reasonable best efforts to promptly transfer, or cause to
be transferred to GSK, a copy of Unigene Know-How relating to PTH and the
Licensed Product, including manufacture of API, to enable GSK to carry out its
responsibilities under this Agreement.  Such data shall include, at a minimum,
the information set forth in Appendix C to this Agreement, attached hereto and
incorporated herein.

                                   ARTICLE 5
                            SUPPLY AND MANUFACTURE

     5.1.  Preclinical and Phase I Clinical Supply of API.  Within ninety (90)
           ----------------------------------------------
days after the Effective Date,  the Parties shall negotiate the terms of
supply for preclinical and Phase I clinical supply of API (the "Phase I Supply
Agreement"). The Phase I Supply Agreement will include, but not be limited to
terms covering the, quality, specifications, quantity (which at a minimum shall
be ** (**) ** of research grade API and ** (**) ** of GMP grade API), payment,
batch failure, change control, regulatory/audits, audit rights for GSK
consistent with the rights granted to Unigene in Section 3.14, information
related to manufacture of API, QA release and testing and shipping requirements.
All supply of API under the Phase I Supply Agreement shall be at **.  For
avoidance of doubt, GSK shall be responsible for conversion of API into Licensed
Product for use in preclinical work and in Phase I.

     5.2.  Additional API Supply.  At the appropriate time, the Parties shall
           ---------------------
negotiate in good faith the terms of supply for API for further GSK clinical
development or commercialization of Licensed Product, such terms to include a
supply price for API set at **. Notwithstanding this Section 5.2, GSK shall
reserve the right to supply its requirements of API and/or Licensed Product
(which Licensed Product can be supplied either alone or from a contract
manufacturer, subject to Section 2.1.2(b)) in order to develop and commercialize
Licensed Product for GSK and/or its Affiliates and sublicensees.

     5.3.  Transfer of Manufacturing Technology from Unigene.  At the
           -------------------------------------------------
appropriate time, the Parties shall coordinate the transfer of manufacturing
technology not previously transferred

                                       20
<PAGE>

pursuant to Section 4.5 to enable GSK to procure its own supply of API and/or
Licensed Product.  The Unigene FTEs required for the transfer of manufacturing
technology are outlined in the Work Plan and shall be included in the Project
Team in accordance with Section 4.4

                                   ARTICLE 6
                             INTELLECTUAL PROPERTY

     6.1.  Ownership of Inventions.
           -----------------------

           6.1.1.  Inventions.  With respect to inventions and intellectual
                   ----------
property relating to Licensed Product or work performed under this Agreement
arising during the Term: (i) title to all inventions and intellectual property
made solely by Unigene employees or its agents without inventive contribution by
GSK employees or its agents shall be owned by Unigene (each, a "Unigene
Invention"); (ii) title to all inventions and intellectual property made solely
by GSK employees or its agents hereunder without inventive contribution by
Unigene employees or its agents shall be owned by GSK (each, an "GSK
Invention"); and (iii) title to all inventions and intellectual property made
jointly by employees or the agents of GSK and Unigene (each a "Joint Invention")
shall be jointly owned by Unigene and GSK.

           6.1.2.  Inventorship.  Inventorship and rights of ownership of
                   ------------
inventions and other intellectual property rights conceived and/or reduced to
practice in connection with the development activities hereunder shall be
determined in accordance with the patent laws of the United States.  It is
understood that (i) except with respect to the rights granted and reserved
pursuant to Section 6.2 and (ii) as to all Joint Inventions other than JOINT
Patent RIGHTS in the Field which are subject to the license granted in Section
2.1 and for the duration of such license, neither Party shall have any
obligation to account to the other for profits, or to obtain any approval of the
other Party to license, assign, mortgage or exploit a Joint Invention by reason
of joint ownership of any such intellectual property, and may otherwise
undertake all activities a sole owner might undertake with respect to such
inventions without the consent and without accounting to the other joint owner,
except as otherwise provided in this Agreement or as the Parties may otherwise
agree in writing.

     6.2.  License to Unigene.
           ------------------

           6.2.1. GSK hereby grants to Unigene an exclusive (even as to GSK),
world wide, perpetual, irrevocable license, with the right to grant sublicenses,
under GSK Inventions and GSK's interest in Joint Inventions developed with the
use of Unigene Know-How (other than Unigene Inventions) and which GSK Inventions
and Joint Inventions constitute improvements, modifications and/or enhancements
of such Unigene Know-How ("Dependent GSK Improvements") for all purposes,
including, but not limited to, making, having made, using, selling, offering to
sell, developing, marketing, and distributing drug product, all subject to the
reservation of rights in Section 6.2.2, and the license grants in Section 2.1.

                                       21
<PAGE>

           6.2.2. Notwithstanding anything in this Article 6 to the contrary,
and subject to the licenses granted in Section 2.1, GSK reserves the right,
under all Dependent GSK Improvements and otherwise under all GSK Inventions and
GSK's interest in Joint Inventions, to make, have made, use, sell, offer for
sale and import Licensed Products in the Territory in the Field. The Parties
further agree that upon GSK's request that the Parties enter into good faith
negotiations regarding the grant of royalty-bearing rights back to GSK under the
GSK Inventions and GSK's interest in Joint Inventions to commercialize drug
product other than Licensed Product in the Territory in the Field, in the event
Unigene has not granted, or is not presently in discussions regarding the grant
of, such rights to a Third Party, the Parties shall enter into such negotiations
which shall recognize the contributions of each Party to such invention.

     6.3.  Disclosure of Unigene Patent Rights.  Unigene warrants and represents
           -----------------------------------
that it has disclosed to GSK the complete texts of all patent applications filed
by Unigene as of the Effective Date which relate to Licensed Product as well as
all information received as of the Effective Date concerning the institution or
possible institution of any interference, opposition, re-examination, reissue,
revocation, nullification or any official proceeding involving a Unigene Patent
Right anywhere in the Territory. Unigene further warrants and represents that it
will disclose to GSK the complete texts of all patent applications filed by
Unigene after the Effective Date which relate to Licensed Product as well as all
information received after the Effective Date concerning the institution or
possible institution of any interference, opposition, re-examination, reissue,
revocation, nullification or any official proceeding involving a Unigene Patent
Right anywhere in the Territory. GSK shall have the right to review all such
pending applications and other proceedings and make recommendations to Unigene
concerning them and their conduct. Unigene agrees to keep GSK promptly and fully
informed of the course of patent prosecution or other proceedings by means that
include providing GSK with copies of substantive communications, search reports
and Third Party observations submitted to or received from patent offices
throughout the Territory. GSK shall provide such patent consultation to Unigene
at no cost to Unigene and shall treat all information disclosed to it under this
Section as confidential and subject to the provisions of this Agreement.

     6.4.  Filing, Prosecution, Maintenance.  Each Party shall promptly notify
           --------------------------------
the other, and each shall likewise inform the JDC on at least a quarterly basis,
upon the making, conceiving or reducing to practice of any intellectual
property, invention or discovery referred to in Section 6.1.1. With respect to
any such invention:

           (a)  GSK shall have the first right, using in-house or outside legal
counsel selected at GSK's sole discretion, to prepare, file, prosecute, maintain
and extend patent applications and patents concerning all such inventions and
discoveries owned in whole by GSK or jointly by GSK and Unigene in countries of
GSK's choice throughout the Territory with appropriate credit to Unigene
representatives, including the naming of such Parties as inventors where
appropriate and in accordance with the relevant legal requirements, for which
GSK shall bear the costs relating to such activities which occur at GSK's
request or direction. GSK shall solicit Unigene's advice and review of the
nature and text of any such patent applications to the extent such are related
to Licensed Products and important prosecution matters related thereto

                                       22
<PAGE>

in reasonably sufficient time prior to filing thereof, and GSK shall take into
account Unigene's reasonable comments related thereto.

          (b)  Unigene shall have the first right, using in-house or outside
legal counsel selected at Unigene's sole discretion, to prepare, file,
prosecute, maintain and extend patent applications and patents concerning all
such inventions and discoveries owned in whole by Unigene, as well as all other
Unigene Patent Rights, in countries of Unigene's choice throughout the
Territory, for which Unigene shall bear the costs. Unigene shall solicit GSK's
advice and review of the nature and text of such patent applications to the
extent such are related to Licensed Products and important prosecution matters
related thereto in reasonably sufficient time prior to filing thereof, and
Unigene shall take into account GSK's reasonable comments related thereto.

          (c)  If GSK, prior or subsequent to filing patent applications on any
GSK Inventions or a Joint Invention in the Territory elects not to file,
prosecute or maintain such patent applications or ensuing patents or claims
encompassed by such patent applications or ensuing patents in any country of the
Territory, as the case may be, GSK shall give Unigene notice thereof within a
reasonable period prior to allowing such patent applications or patents or such
claims encompassed by such patent applications or patents to lapse or become
abandoned or unenforceable, and Unigene shall thereafter have the right, at its
sole expense, to prepare, file, prosecute and maintain patent applications and
patents or divisional applications related to such claims encompassed by such
patent applications or patents concerning all such inventions and discoveries in
countries of its choice throughout the world.

          (d)  If Unigene, prior or subsequent to filing patent applications on
any Unigene Patent Rights including Unigene Inventions which are owned in whole
by Unigene and Unigene elects not to file, prosecute or maintain such patent
applications or ensuing patents or claims encompassed by such patent
applications or ensuing patents in any country of the Territory, Unigene shall
give GSK notice thereof within a reasonable period prior to allowing such patent
applications or patents or such claims encompassed by such patent applications
or patents to lapse or become abandoned or unenforceable, and GSK shall
thereafter have the right, at its sole expense, to prepare, file, prosecute and
maintain patent applications and patents or divisional applications related to
such claims encompassed by such patent applications or patents concerning all
such inventions and discoveries in countries of its choice throughout the world.

          (e)  The Party filing patent applications for jointly owned inventions
and discoveries shall do so in the name of and on behalf of both GSK and
Unigene. Each of Unigene and GSK shall hold all information it presently knows
or acquires under this Section that is related to all such patents and patent
applications as confidential subject to the provisions of this Agreement.

          (f)  Each Party shall cooperate with the other as reasonably requested
to effect the provisions of this Section 6.4.

                                       23
<PAGE>

     6.5.  Enforcement.
           -----------

           6.5.1. Unigene Patent Rights.  Subject to Section 6.5.2 below, in the
                  ---------------------
event that a Party learns that any Unigene Patent Rights necessary for the
manufacture, use and/or sale of a Licensed Product are infringed or
misappropriated by activities in the Field related to Licensed Product by a
Third Party in any country in the Territory, or is subject to a declaratory
judgment action arising from such infringement in such country, such Party shall
promptly notify the other Party hereto. GSK shall have the initial right (but
not the obligation) to enforce such Unigene Patent Rights, or defend any
declaratory judgment action with respect thereto, at its expense, and to use
Unigene's name in connection therewith; provided that such use without Unigene's
written consent may only occur where required by law for GSK to bring such
action. In the event that GSK fails to initiate a suit to enforce such Unigene
Patent Rights against such a Third Party in any jurisdiction in the Territory
within ninety (90) days after notification of such infringement, Unigene may
initiate such suit in the name of the Unigene with regard to the applicable
Unigene Patent RightS against such infringement, at the expense of Unigene, and
to use GSK's name in connection therewith. The Party involved in any such claim,
suit or proceeding (the "Enforcing Party"), shall keep the other Party hereto
reasonably informed of the progress of any such claim, suit or proceeding.
Unigene and GSK shall recover their respective actual out-of-pocket expenses, or
equitable proportions thereof, associated with any litigation or settlement
thereof from any recovery made by any Party. Any excess amount shall be
distributed between the Enforcing Party and the other party in the ratio
equivalent to the profit GSK derives from Licensed Product in the Territory
relative to the royalty Unigene derives from Licensed Product in the Territory,
with the Enforcing Party receiving the larger proportion of the excess amount,
provided that in no event shall a Party receive a proportion of the excess
amount less than the proportion of the total out-of-pocket expenses paid by such
Party.

           6.5.2. Jointly Owned Patents.  Notwithstanding Section 6.5.1 above,
                  ---------------------
in the event that any patent that is jointly owned by Unigene and GSK under
Section 6.1 of this Agreement is infringed or misappropriated by a Third Party,
GSK and Unigene shall discuss whether, and, if so, how, to enforce such jointly
owned patent or defend such jointly owned patent in an infringement action,
declaratory judgment or other proceeding. In the event only one Party wishes to
participate in such proceeding, it shall have the right to proceed alone, at its
expense, and may retain any recovery; provided, at the request and expense of
the participating Party, the other Party agrees to cooperate and join in any
proceedings in the event that a Third Party asserts that the co-owner of such
Joint Invention is necessary or indispensable to such proceedings.

     6.6.  Infringement Claims.  If the manufacture, sale or use of any Licensed
           -------------------
Product in the Territory pursuant to this Agreement results in any claim, suit
or proceeding alleging patent infringement against Unigene or GSK, such Party
shall promptly notify the other Party hereto. If GSK is not named as a Party in
such a claim, suit or proceeding, GSK may, at its own expense and through
counsel of its own choice, seek leave to intervene in such claim, suit or
proceeding. Unigene agrees not to oppose such intervention. If GSK, and not
Unigene, is named as a Party

                                       24
<PAGE>

to such claim, suit or proceeding, GSK shall have the right to control the
defense and settlement of such claim, suit or proceeding, at its own expense,
using counsel of its own choice, however Unigene, at its own expense and through
counsel of its own choice, may seek to intervene if the claim, suit or
proceeding relates to the commercialization of the Licensed Product in the
Field, and in such event, GSK agrees not to oppose such intervention. If GSK is
named as a Party and Unigene shall, at any time, tender its defense to GSK, then
GSK shall defend Unigene in such claim, suit or proceeding, at GSK's own expense
and through counsel of its own choice, and GSK shall control the defense and
settlement of any such claim, suit or proceeding; provided, GSK shall not enter
into any agreement which (i) extends or purports to exercise GSK's rights under
Unigene's Licensed Technology beyond the rights granted pursuant to this
Agreement, (ii) makes any admission regarding (a) wrongdoing on the part of
Unigene, or (b) the invalidity, unenforceability or absence of infringement of
any Unigene Patent Rights or patent claiming a Joint Invention, without the
prior written consent of Unigene, which consent shall not be unreasonably
withheld. The Parties shall cooperate with each other in connection with any
such claim, suit or proceeding and shall keep each other reasonably informed of
all material developments in connection with any such claim, suit or proceeding.
Nothing in this Section 6.5 shall limit or modify the provisions of Article 9,
which may apply to such infringement claims as discussed herein.

     6.7.  Litigation Activities Update.  The Parties shall keep one another
           ----------------------------
informed of the status of and of their respective activities regarding any
litigation or settlement thereof concerning Licensed Product, provided however
that no settlement or consent judgment or other voluntary final disposition of
any suit defended or action brought by a Party pursuant to this Article 6 may be
entered into without the written consent of the other Party, which consent shall
not be unreasonably withheld or delayed.

     6.8.  GSK's Extensions of Unigene Patent Rights, Pipeline Protection and
           ------------------------------------------------------------------
Supplementary Patent Certificates ("SPCs")
------------------------------------------

           6.8.1. Patent Extensions.  GSK shall have the right but not the
                  -----------------
obligation to seek extensions of the terms of Unigene Patent Rights. At GSK's
request, Unigene shall either authorize GSK to act as Unigene's agent for the
purpose of making any application for any extensions of the term of Unigene
Patent Rights and provide reasonable assistance therefor to GSK or shall
diligently seek to obtain such extensions, in either event, at GSK's expense.

           6.8.2. SPCs. At GSK's request and expense, Unigene shall seek to
                  ----
obtain SPCs based on Unigene Patent Rights or authorize GSK to obtain SPCs based
on Unigene Patent RightS on Unigene's behalf. Where GSK holds a relevant
Marketing Authorization, GSK shall at its sole discretion provide to Unigene a
copy of said Marketing Authorization and any information necessary for the
purpose of obtaining an SPC based on a Unigene Patent Right.

           6.8.3. Pipeline Protection  At GSK's request and expense, Unigene
                  -------------------
shall cooperate with GSK to obtain "pipeline" protection for Unigene Patent
RightS which may be available under the patent laws of countries in the
Territory in which the patent laws thereof are amended to provide improved
protection for Licensed Product.

                                       25
<PAGE>

           ** Certain information on this page has been omitted and filed
           separately with the Commission. Confidential treatment has been
           requested with respect to the omitted portions.

     6.9.  Unigene's Additional Patent Protection.  Notwithstanding Sections
           --------------------------------------
6.8.1 and 6.8.2, Unigene shall have the right, but not the obligation, to seek
extensions of the terms of Unigene Patent Rights and to seek to obtain SPCs
based on Unigene Patent Rights at its own expense. At Unigene's request, GSK
shall provide to Unigene a copy of any requested NDA or MAA where GSK holds such
NDA or MAA, and any information necessary for the purpose of seeking such
extensions of Unigene Patent Rights and obtaining SPCs.

     6.10. Trademarks.  GSK, its Affiliates, and its sublicensees shall have the
           ----------
right to market Licensed Product under their own labels, tradenames, and
trademark(s) (collectively, the "GSK Marks") and GSK shall solely own such
trademarks, labels and tradenames. GSK shall be responsible for the selection of
all GSK Marks that it employs in connection with Licensed Product in the
Territory and shall own and control such GSK Marks and retain ownership upon
termination or expiration of this Agreement, except as provided in Section
10.5.6. GSK shall be responsible for filing, registering and maintaining all GSK
Marks throughout the Territory.

                                   ARTICLE 7
                        REPRESENTATIONS AND WARRANTIES

     7.1.  Warranties.
           ----------

           7.1.1. Unigene.  Unigene warrants and represents to GSK that:
                  -------

     (i)   as of the Effective Date, and except as otherwise disclosed to GSK,
           it has full Control of the Licensed Technology to grant the rights
           and licenses granted hereunder, and that it otherwise has the full
           right and authority to enter into this Agreement;

     (ii)  as of the Effective Date, there are no existing or threatened
           actions, suits or claims pending against it with respect to the
           Licensed Technology or its right to enter into and perform its
           obligations under this Agreement;

     (iii) as of the Effective Date, it has not granted, and will not grant
           during the Term of this Agreement, any right, license or interest in
           or to the Licensed Technology that is in conflict with the rights or
           licenses granted under this Agreement, nor as of the Effective Date,
           has it encumbered any Unigene Know-How and/or Unigene Patent RightS,
           except as set forth on Appendix D, attached hereto and incorporated
           herein;

     (iv)  there is nothing in any Third Party agreement Unigene has entered
           into as of the Effective Date, and, with respect to the ** License
           Agreement and the ** License Agreement, after the Effective Date,
           which, in any way, will limit Unigene's ability to perform all of the
           obligations undertaken by Unigene hereunder, and that it will not
           enter into any agreement after the Effective Date under which Unigene
           would incur any such limitations;

                                       26
<PAGE>

            ** Certain information on this page has been omitted and filed
            separately with the Commission. Confidential treatment has been
            requested with respect to the omitted portions.

     (v)    as of the Effective Date, and subject to its obligation to grant a
            sublicense to GSK to ** IP and the ** Patent, it has no knowledge
            from which it concludes that the Unigene Patent Rights are invalid
            or that their exercise would infringe patent rights of Third
            Parties, and it has no knowledge, as of the Effective Date, from
            which it concludes that the process by which it manufactures API or
            Licensed Product, or anticipated components thereof, and all
            intermediates of such process, would infringe patent rights of Third
            Parties in any country in which the API or Licensed Product, or
            anticipated components thereof, is produced as well as in all
            countries of the Territory;

     (vi)   as of the Effective Date, other than with respect to a certain
            preclinical study performed by a Third Party which compared the
            activity of various PTH molecules completed within the last six (6)
            months, which study Unigene has disclosed to GSK, Unigene has not
            intentionally omitted to furnish GSK with any information requested
            by GSK, nor intentionally concealed from GSK, any information in its
            possession concerning PTH or Licensed Product, or anticipated
            components thereof, or the transactions contemplated by this
            Agreement, which would be material to GSK's decision to enter into
            this Agreement and to undertake the commitments and obligations set
            forth herein;

     (vii)  it has not intentionally concealed from GSK the existence of any
            pre-clinical or clinical data or information concerning PTH or the
            Licensed Product, or anticipated components thereof, which suggests
            that there may exist quality, toxicity, safety and/or efficacy
            concerns which may materially impair the utility and/or safety of
            PTH or the Licensed Product, or anticipated components thereof;

     (viii) it will perform all of its obligations under the ** License
            Agreement and ** License Agreement, will maintain such agreements in
            full force and effect, and will not terminate or amend the **
            License Agreement and ** License Agreement without GSK's written
            approval; and

            7.1.2.  GSK.  GSK warrants and represents to Unigene that:
                    ---

     (i)    as of the Effective Date, it has the full right and authority to
            enter into this Agreement;

     (ii)   as of the Effective Date, there are no existing or threatened
            actions, suits or claims pending against it with respect to its
            right to enter into and perform its obligations under this
            Agreement;

     (iii)  as of the Effective Date, it has not granted, and it will not grant
            during the Term of this Agreement, any right, license or interest in
            or to the Licensed Technology, GSK Patent Rights, GSK Know-How,
            Joint Patent Rights, and/or Joint

                                       27
<PAGE>

            ** Certain information on this page has been omitted and filed
            separately with the Commission. Confidential treatment has been
            requested with respect to the omitted portions.

            Inventions which is in conflict with the rights or licenses granted
            to Unigene under this Agreement;

     (iv)   there is nothing in any Third Party agreement GSK has entered into
            as of the Effective Date, which, in any way, will limit GSK's
            ability to perform all of the obligations undertaken by GSK
            hereunder, and that it will not enter into any agreement after the
            Effective Date under which GSK would incur any such limitations;

     (v)    as of the Effective Date, to the best of its knowledge, it has no
            knowledge of any matter which would allow GSK to terminate the
            Agreement pursuant to Article 10.4, nor has it intentionally omitted
            to furnish Unigene with any information requested by GSK, nor has it
            intentionally concealed from Unigene any information in its
            possession concerning PTH or Licensed Product, or anticipated
            components thereof, or the transactions contemplated by this
            Agreement, which would be material to Unigene's decision to enter
            into this Agreement and to undertake the commitments and obligations
            set forth herein; and

     (vi)   it is not a party to any agreement or arrangement with any Third
            Party or under any obligation or restriction which in any way limits
            or conflicts with its ability to fulfill any of its obligations
            under this Agreement, and shall not enter into any such agreement or
            arrangement during the Term of this Agreement.

     7.2.   Covenant of Unigene Regarding ** and **. Unigene covenants that it
            ---------------------------------------
shall use its reasonable best efforts to execute the ** and **.

     7.3.   Limits on Competition.  Each Party warrants and represents to the
            ---------------------
other that, during the Term, it will not enter into any agreement with any Third
Party relating to the development of a drug product for oral administration
containing or incorporating PTH. In the event that GSK is considering the
development of a drug product other than Licensed Product, using the identical
PTH molecule as is used in a License Product, before GSK begins development, GSK
will provide notice to Unigene of the contemplated development, and the parties
shall enter into good faith discussions regarding the development of such
product, and the use of Unigene technology therein. This Section 7.3 does not
limit in any way the scope or exclusivity of the license grants in Section 2.

                                       28
<PAGE>

                                  ARTICLE 8
                  CONFIDENTIALITY AND EXCHANGE OF INFORMATION

     8.1.  Confidential Information.  Except as expressly provided herein, the
           ------------------------
Parties agree that, for the Term of this Agreement and for five (5) years
thereafter, the receiving Party shall keep completely confidential and shall not
publish or otherwise disclose and shall not use for any purpose except for the
purposes contemplated by this Agreement any Confidential Information furnished
to it by the disclosing Party hereto pursuant to this Agreement, except that to
the extent that it can be established by the receiving Party by competent proof
that such Confidential Information:

           (1)  was already known to the receiving Party, other than under an
obligation of confidentiality, at the time of disclosure;

           (2)  was generally available to the public or otherwise part of the
public domain at the time of its disclosure to the receiving Party;

           (3)  became generally available to the public or otherwise part of
the public domain after its disclosure and other than through any act or
omission of the receiving Party in breach of this Agreement;

           (4)  was independently developed by the receiving Party without
reference to any information or materials disclosed by the disclosing Party; or

           (5)  was subsequently disclosed to the receiving Party by a person
other than a Party without breach of any legal obligation to the disclosing
Party.

     8.2.  Permitted Disclosures.  Each Party hereto may disclose the other's
           ---------------------
Confidential Information to the extent such disclosure is reasonably necessary
in connection with the conduct of the development activities to be conducted
hereunder, in filing or prosecuting patent applications, prosecuting or
defending litigation, complying with applicable governmental regulations or
otherwise submitting information to tax or other governmental authorities,
conducting clinical trials, or making a permitted sublicense or otherwise
exercising its rights hereunder, provided that if a Party is required to make
any such disclosure of another Party's Confidential Information, other than
pursuant to a confidentiality agreement, it will give reasonable advance notice
to the latter Party of such disclosure and, save to the extent inappropriate in
the case of patent applications, will use its best efforts to secure
confidential treatment of such information prior to its disclosure (whether
through protective orders or otherwise).

     8.3.  Public Announcements.   No public announcement or other disclosure to
           --------------------
Third Parties concerning the existence of, terms, or subject matter of this
Agreement shall be made, either directly or indirectly, by any Party to this
Agreement, except as may be legally required or as may be required for recording
purposed, without first obtaining the approval of the other Party and agreement
upon the nature and text of such announcement or disclosure. The Party desiring

                                       29
<PAGE>

to make any such public announcement or other disclosure (including those which
are legally required or may be required for recording purposes) shall inform the
other Party of the proposed announcement or disclosure in reasonably sufficient
time prior to public release, which shall be at least five (5) business days
prior to release of such proposed announcement or disclosure, and shall provide
the other Party with a written copy thereof, in order to allow such other Party
to comment upon such announcement or disclosure. Each Party agrees that it shall
cooperate fully with the other with respect to all disclosures regarding this
Agreement to the Securities Exchange Commission and any other governmental or
regulatory agencies, including requests for confidential treatment of
proprietary information of either Party included in any such disclosure.
Notwithstanding the foregoing, the Parties shall agree upon a press release to
announce the execution of this Agreement, together with a corresponding Q&A
outline for use in responding to inquiries about the Agreement; thereafter,
Unigene and GSK may each disclose to Third Parties the information contained in
such press release and Q&A without the need for further approval by the other.

     8.4.  Publications.  Nothing herein shall be construed to prevent GSK from
           ------------
disclosing any information received from Unigene hereunder to an Affiliate,
sublicensee, distributor, Third Party research or clinical contractor of GSK,
provided, in the case of a sublicensee, distributor or Third Party research or
clinical contractor of GSK, such sublicensee, distributor, or Third Party
research or clinical contractor of GSK has undertaken a similar obligation of
confidentiality with respect to the Confidential Information. Neither Party
shall not submit for written or oral publication any manuscript, abstract or the
like which includes data or other information pertaining to Licensed Product
without first obtaining the prior written consent of the other Party, which
consent shall not be unreasonably withheld, and shall be promptly given or
refused.

     8.5.  Bankruptcy.  All Confidential Information disclosed by one Party to
           ----------
the other shall remain the intellectual property of the disclosing Party. In the
event that a court or other legal or administrative tribunal, directly or
through an appointed master, trustee or receiver, assumes partial or complete
control over the assets of a Party to this Agreement based on the insolvency or
bankruptcy of such Party, the bankrupt or insolvent Party shall promptly notify
the court or other tribunal (i) that Confidential Information received from the
other Party under this Agreement remains the property of the other Party, and
(ii) of the confidentiality obligations under this Agreement. In addition, the
bankrupt or insolvent party shall, to the extent permitted by law, take all
steps necessary or desirable to maintain the confidentiality of the other
party's Confidential Information and to ensure that the court, other tribunal or
appointee maintains such information in confidence in accordance with the terms
of this Agreement.

                                   ARTICLE 9
                                INDEMNIFICATION

     9.1.  Indemnification of GSK.  Unigene shall indemnify and hold harmless
           ----------------------
GSK and its Affiliates, and their respective directors, officers, employees,
agents and counsel, and the

                                       30
<PAGE>

successors and assigns of the foregoing (the "GSK Indemnitees"), from and
against any and all liabilities, damages, losses, costs or expenses (including
reasonable attorneys' and professional fees and other expenses of litigation
and/or arbitration) resulting from a claim, suit or proceeding brought by a
Third Party against a GSK Indemnitee, arising from or occurring as a result of:
(i) the failure of API manufactured and supplied by Unigene to meet on delivery
the Specifications agreed by the Parties, or (ii) the failure by Unigene to
obtain or maintain rights under Unigene Patent Rights sufficient to grant GSK an
exclusive license in accordance with Article 2 of this Agreement; or (iii)
Unigene's material breach of any representation or warranty set forth in Section
7.1.1, except, in each case, to the extent caused by the negligence or willful
misconduct of GSK or to the extent that GSK is obligated to indemnify Unigene
under Section 9.2 below. It is understood that the foregoing indemnity under
Section 9.1 shall not include any lost profits or consequential damages.

     9.2.  Indemnification of Unigene.  GSK and its Affiliates and sublicensees
           --------------------------
shall indemnify and hold harmless Unigene and its Affiliates and their
respective directors, officers, employees, agents and counsel and the successors
and assigns of the foregoing (the "Unigene Indemnitees"), from and against any
and all liabilities, damages, costs or expenses (including reasonable attorneys'
and professional fees and other expenses of litigation and/or arbitration)
resulting from a claim, suit or proceeding brought by a Third Party against a
Unigene Indemnitee, arising from or occurring as a result of: (i) the conduct of
clinical trials and development activities hereunder by GSK or its Affiliates or
sublicensees, or (ii) the development, manufacture, marketing and/or
commercialization of any Licensed Product by GSK or its Affiliates or
sublicensees (including without limitation, Licensed Product liability claims);
or (iii) GSK's material breach of any representation or warranty set forth in
Section 7.1.2 except, in each case, to the extent caused by the negligence or
willful misconduct of Unigene or to the extent that Unigene is obligated to
indemnify GSK under Section 9.1. It is understood that the foregoing indemnity
under Section 9.2 shall not include any lost profits or consequential damages.

     9.3.  Procedure.  A Party (the "Indemnitee") that intends to claim
           ---------
indemnification under this Article 9 shall promptly notify the other Party (the
"Indemnitor") in writing of any loss, claim, damage, liability or action in
respect of which the Indemnitee or any of its Affiliates, sublicensees or their
directors, officers, employees, agents or counsel intend to claim such
indemnification, and the Indemnitor shall have the right to participate in, and,
to the extent the Indemnitor so desires, to assume the defense thereof with
counsel mutually satisfactory to the Parties. The indemnity agreement in this
Article 9 shall not apply to amounts paid in settlement of any loss, claim,
damage, liability or action if such settlement is made without the consent of
the Indemnitor, which consent shall not be withheld unreasonably. The failure to
deliver written notice to the Indemnitor within a reasonable time after the
commencement of any such action, if prejudicial to its ability to defend such
action, shall relieve such Indemnitor of any liability to the Indemnitee under
this Article 9. At the Indemnitor's request, the Indemnitee under this Article
9, and its employees and agents, shall cooperate fully with the Indemnitor and
its legal representatives in the investigation and defense of any action, claim
or liability covered by this indemnification and provide full information with
respect thereto.

                                       31
<PAGE>

              **Certain information on this page has been omitted and filed
              separately with the Commission. Confidential treatment has been
              requested with respect to the omitted portions.

                                  ARTICLE 10
                             TERM AND TERMINATION

     10.1.    Term and Early Termination by GSK. This Agreement shall be
              ---------------------------------
effective as of the Effective Date. If Unigene fails to **, GSK, in its sole
discretion, may, by written notice to Unigene, immediately terminate this
Agreement. After the Effective Date, unless this Agreement is otherwise
terminated earlier pursuant to this Section 10.1 or pursuant to the other
provisions of this Article 10, this Agreement shall continue in full force and
effect on a Licensed Product-by-Licensed Product and country-by-country basis
until the date GSK and its Affiliates and sublicensees have no remaining royalty
obligations in such country in accordance with Sections 10.1.1, 10.1.2 and
10.1.3.

     10.1.1.  Royalty Expiration where Valid Claim Exists. obligations under
              -------------------------------------------
Section 3.4 in each country of the Territory shall expire upon the expiration or
invalidation of the last remaining issued Unigene Formulation Patent Right in
such country, which claims the Licensed Product sold. Expiration of GSK's
royalty obligations under Section 3.4 for a particular Licensed Product under
this provision shall not preclude GSK from continuing to market such Licensed
Product and to use Unigene Patent Rights and Unigene Know-How in such country
without further royalty payments or any other remuneration to Unigene, except to
the extent that Section 3.5 is still applicable to the Net Sales of the
particular Licensed Product in the particular country.

     10.1.2.  Royalty Expiration where No Valid Claim Exists. Royalty
              ----------------------------------------------
obligations under Section 3.5 in each country shall expire upon the ** (**)
anniversary of the date of First Commercial Sale in such country. Expiration of
GSK's royalty obligations for a particular Licensed Product under this provision
shall not preclude GSK from continuing to market such Licensed Product and to
use Unigene Know-How in such country without further royalty payments or any
other remuneration to Unigene.

     10.1.3.  Royalty Expiration. Upon expiration of GSK's royalty obligations
              ------------------
under Sections 10.1.1 and 10.1.2, GSK shall have a fully paid up, royalty free,
perpetual, irrevocable, non-exclusive, world wide license, with the right to
sublicense subject to this Section 10.1.3, and GSK shall be free to make, have
made, use and sell Licensed Product and to use Unigene Know-How in the
Territory, without further royalty payments or any other remuneration to
Unigene. GSK's right to sublicense as to making and having made API shall be
subject to Section 2.1 for any new subcontracts to manufacture API or PTH
entered into by GSK after expiration of GSK's royalty obligations under Sections
10.1.1 and 10.1.2., but only with respect to a Third Party with which GSK had
not subcontracted prior to the expiration of its royalty obligations, which
Third Party shall continue to be subject to confidentiality obligations no less
stringent than those set forth in Article 8.

                                       32
<PAGE>

     10.2. Termination for Material Breach.  Either Party may terminate this
           -------------------------------
Agreement in the event the other Party has materially breached or defaulted in
the performance of any of its obligations hereunder, and if such default is not
corrected within sixty (60) days after receiving written notice from the other
Party with respect to such default, such other Party shall have the right to
terminate this Agreement by giving written notice to the Party in default,
provided the notice of termination is given within one (1) year of when the
Party giving notice knew or should have known of the default and prior to
correction of the default; provided that the time period for providing such
notice of termination shall be extended for so long as the Parties are engaged
in good faith negotiations to resolve the situation. Notwithstanding the above,
in the case of a failure of GSK to pay any royalty due hereunder, the period for
cure of any such failure to pay following notice from Unigene thereof shall be
thirty (30) days and, unless payment is made by GSK within such period or unless
GSK has notified Unigene that a good faith dispute exists regarding GSK's
failure to pay, the termination shall become effective at the end of such thirty
(30) day period.

     10.3. Termination for Insolvency; Retention of License.  If voluntary or
           ------------------------------------------------
involuntary proceedings by or against a Party are instituted in bankruptcy under
any insolvency law, or a receiver or custodian is appointed for such Party, or
proceedings are instituted by or against such Party for corporate reorganization
or the dissolution of such Party, which proceedings, if involuntary, shall not
have been dismissed within sixty (60) days after the date of filing, or if such
Party makes an assignment for the benefit of creditors, or substantially all of
the assets of such Party are seized or attached and not released within sixty
(60) days thereafter, the other Party may immediately terminate this Agreement
effective upon notice of such termination. Notwithstanding the bankruptcy of a
Party, or the impairment of performance by a Party of its obligations under this
Agreement as a result of bankruptcy or insolvency of such Party, and subject to
such Party's rights to terminate this Agreement for reasons other than
bankruptcy or insolvency as expressly provided in this Agreement, the other
Party shall be entitled to retain the licenses under the terms and conditions
granted herein.

     10.4. Termination by GSK.  At any time after one (1) year after the
           ------------------
Effective Date, GSK may terminate this Agreement in its sole discretion on a
country-by-country basis, or in its entirety, by giving Unigene at least ninety
(90) days written notice (with such written notice to include a reasonably
detailed explanation of the reasons for the termination, including the
applicable provision of this Section 10.4 and the supporting evidence therefore)
thereof at any time for any of the reasons set forth below based on a reasonable
determination by GSK, using the same standards GSK would use in assessing
whether or not to continue development or commercialization of a product of its
own making in its own portfolio, that:

     (i)   the Licensed Product has:

           (1) safety concerns which do not justify continued development or
commercialization, would significantly disadvantage the Licensed Product with
respect to other compounds or products and/or would significantly reduce the
value of the opportunity, all in GSK's reasonable business determination; or

                                       33
<PAGE>

           (2) efficacy concerns which do not justify continued development or
commercialization, or would significantly disadvantage the Licensed Product with
respect to other compounds or products and/or would significantly reduce the
value of the opportunity, all in GSK's reasonable business determination; or

           (3) substantial difficulty in meeting developmental timelines; or

           (4) substantial increases in development costs from current
projections;

     (ii)  the cost of goods for commercial supply of Licensed Product would
           significantly reduce the value of the opportunity;

     (iii) changes to the osteoporosis market and/or the competitive environment
           reduce the sales forecast below a commercially viable threshold
           normally applied by GSK within its own portfolio;

     (iv)  government, regulatory or another recognized institution imposes a
           new law or requirement, or establishes guidelines or a pattern of
           practice, which means:

           (1) the continued development or commercialization of the Licensed
Product violates such a law or requirement, or

           (2) the value of the opportunity is significantly reduced, or

           (3) the pricing and/or reimbursement environment has changed in such
a way as to significantly reduce the projected value of the opportunity, or

           (4) a condition in (i) or (iii) above becomes applicable.

     10.5. General Effect of Termination.
           -----------------------------

           10.5.1.  Accrued Obligations.  Termination of this Agreement for any
                    -------------------
reason shall not release any Party hereto from any liability which, at the time
of such termination, has already accrued to the other Party or which is
attributable to a period prior to such termination, nor preclude either Party
from pursuing any rights and remedies it may have hereunder or at law or in
equity which accrued or are based upon any event occurring prior to such
termination.

           10.5.2.  Return of Materials.  Upon any termination of this
                    -------------------
Agreement, GSK and Unigene shall promptly return to the other Party all
materials and tangible Confidential Information received from the other Party
(except one copy of which may be retained by legal counsel for archival
purposes).

           10.5.3.  Stock on Hand.  In the event this Agreement is terminated
                    -------------
for any reason after commencement of commercial sales of Licensed Product by GSK
and/or its Affiliates and sublicensees, GSK and its Affiliates and sublicensees
shall have the right to sell (as to Licensed Product only) or otherwise dispose
of the stock of any API, PTH and Licensed Products then

                                       34
<PAGE>

on hand for a period of six (6) months after the date of termination, subject to
Article 3 and the other applicable terms of this Agreement, including, but not
limited to, royalty obligations.

     10.6. Licenses.  In the event of termination by GSK pursuant to Section
           --------
10.1, 10.3 or 10.4 or termination by Unigene under Section 10.2 due to GSK's
material breach, the licenses granted to GSK under Section 2.1 shall terminate.
In the event of termination by GSK pursuant to Section 10.2 due to Unigene's
material breach, all licenses granted by Unigene to GSK under Section 2.1 shall
survive and continue in full force, and GSK shall be obligated to continue to
make payments under Article 3 to Unigene to the extent GSK continues to develop,
use, market, sell or import PTH or Licensed Product in the Field in the
Territory. In the event of termination by GSK under Section 10.4, or by Unigene
under Section 10.2 or Section 10.4, the licenses granted by GSK to Unigene under
Section 2.3 shall take effect.

           10.6.1.  Regulatory Filings/Approvals.  In the event of termination
                    ----------------------------
by GSK pursuant to Section 10.4, or by Unigene pursuant to Section 10.2 or 10.3,
GSK shall ensure that all regulatory filings and approvals relating to the
Licensed Product are assigned to Unigene (to the extent legally permissible in
the relevant country) within a reasonable time after any termination of GSK's
rights under this Agreement. Any costs incurred by GSK for such assignment or
transfer shall be at GSK's expense. In the event that no such assignment and/or
transfer pursuant to this Section may legally be made, then GSK shall surrender
such regulatory approvals or applications for cancellation. To the extent that
such are related to Licensed Product, all such data, files, materials,
information, filings and approvals shall thereafter be deemed to be Unigene's
Confidential Information and subject to the confidentiality provisions of this
Agreement, and shall be transferred to the possession of Unigene.

           10.6.2.  Trademarks.  In the event of termination by GSK pursuant to
                    ----------
Section 10.3 or 10.4, or by Unigene pursuant to Section 10.2 of 10.3, the
parties shall negotiate in good faith for an assignment by GSK of GSK Marks
which have been used commercially at or prior to said time and are specifically
related to Licensed Product to Unigene (to the extent legally permissible in the
relevant country) within a reasonable time after any termination of GSK's rights
under this Agreement. In the event of termination by Unigene pursuant to Section
10.2, GSK shall assign the GSK Marks specifically related to Licensed Product to
Unigene within a reasonable time after termination of GSK's rights under this
Agreement at no cost or expense to Unigene.

     10.7. Bankruptcy Provisions.  All rights and distribution rights granted
           ---------------------
under or pursuant to the Agreement by Unigene to GSK are, and shall otherwise be
deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code,
licenses of rights to "intellectual property" as defined under Section 101(52)
of the U.S. Bankruptcy Code. The Parties agree that GSK, as licensee of such
rights under this Agreement, shall retain and may fully exercise all of its
rights and elections under the U.S. Bankruptcy Code, subject to performance by
GSK of its preexisting obligations under the Agreement. The Parties further
agree that, in the event of the commencement of a bankruptcy proceeding by or
against Unigene under the U.S. Bankruptcy Code, GSK shall be entitled to a
complete duplicate of (or complete access to, as appropriate)

                                       35
<PAGE>

any such intellectual property and all embodiments of such intellectual
property, and same, if not already in its possession, shall be promptly
delivered to GSK (a) upon any such commencement of a bankruptcy proceeding upon
written request therefore by GSK, unless Unigene elects to continue to perform
all of its obligations under this Agreement, or (b) if not delivered under (a)
above, upon the rejection of this Agreement by or on behalf of Unigene upon
written request therefore by GSK, provided, however, that upon Unigene's (or its
successor's) written notification to GSK that it is again willing and able to
perform all of its obligations under this Agreement, Unigene shall promptly
return all such tangible materials to GSK, but only to the extent that Unigene
does not require continued access to such materials to enable GSK to perform its
obligations under this Agreement.

     10.8. Survival.  Sections 2.4; 3.2, 3.3, 3.4, 3.5, 3.7 and 3.10 (all to the
           --------
extent owed or unpaid) 3.8 and 3.9 (both to the extent owed or unpaid, but only
with respect to activities which occur during the Term), 3.11, 3.12, 3.13, 3.14;
6.1, 6.2, 6.3 (with respect to the representations and warranties therein); 6.5
and 6.6 (both only with respect to infringements which occur during the Term),
6.7 (as applied to any matters surviving under Sections 6.5 and 6.6); 7.1; 8.1
(for the time period provided therein), 8.2, 8.3, 8.5; and Articles 1, 9, 10 and
11 shall survive the expiration or termination of this Agreement for any reason.
In addition, any other provision required to interpret and enforce the Parties'
rights and obligations under this Agreement shall also survive, but only to the
extent required for the observation and performance of the aforementioned
surviving portions of this Agreement.

                                  ARTICLE 11
                                 MISCELLANEOUS

     11.1. Governing Law.  This Agreement shall be deemed to have been made in
           -------------
the Commonwealth of Pennsylvania, U.S.A., and its form, execution, validity,
construction and effect shall be determined in accordance with, and any dispute
arising from the performance or breach hereof shall be governed by and construed
in accordance with, the laws of the Commonwealth of Pennsylvania, without
reference to conflicts of laws principles.

     11.2. Waiver.  Neither Party may waive or release any of its rights or
           ------
interests in this Agreement except in writing. The failure of either Party to
assert a right hereunder or to insist upon compliance with any term or condition
of this Agreement shall not constitute a waiver of that right or excuse a
similar subsequent failure to perform any such term or condition. No waiver by
either Party of any condition or term in any one or more instances shall be
construed as a further or continuing waiver of such condition or term or of
another condition or term

     11.3. Assignment.  This Agreement shall not be assignable by either Party
           ----------
to any Third Party without the written consent of the other Party hereto; except
either Party may assign this Agreement, without such consent, to (i) an
Affiliate of such Party; or (ii) an entity that acquires all or substantially
all of the business or assets of such Party to which this Agreement pertains,
(whether by merger, reorganization, acquisition, sale, or otherwise) and agrees
in writing to be bound by the terms and conditions of this Agreement. The terms
and conditions of this

                                       36
<PAGE>

                 **Certain information on this page has been omitted and filed
                 separately with the Commission. Confidential treatment has been
                 requested with respect to the omitted portions.

Agreement shall be binding on and inure to the benefit of the permitted
successors and assigns of the Parties.

     11.4. Notices.  Any notices, requests and other communications hereunder
           -------
shall be in writing and shall be personally delivered or sent by international
express delivery service, registered or certified air mail, return receipt
requested, postage prepaid, or by facsimile (confirmed by prepaid registered or
certified air mail letter or by international express delivery mail) (e.g.,
FedEx)), and shall be deemed to have been properly served to the addressee upon
receipt of such written communication, to the following addresses of the
Parties, or such other address as may be specified in writing to the other
Parties hereto:

           if to GSK:       GlaxoSmithKline
                            709 Swedeland Road
                            King of Prussia, PA 19406
                            Attention: Senior Vice President, Business
                                          Development
                            Telephone:  **
                            Telecopy:  **

           with copies to:  GlaxoSmithKline
                            Corporate Legal Department
                            One Franklin Plaza
                            200 N. 16/th/ Street/FP 2360
                            Philadelphia, PA 19101
                            Attention:  Senior Vice President and Assistant
                                          General Counsel - R&D Legal Operations
                            Telephone:    215-751-4000
                            Telecopy:     215-751-3935

           if to Unigene:   Unigene Laboratories, Inc.
                            110 Little Falls Road
                            Fairfield, NJ 07004
                            Attention:    President
                            Telephone:    973-882-0860
                            Telecopy:     973-227-6088

           with copy to:    Dechert
                            Princeton Pike Corporate Center
                            P.O. Box 5218
                            Lawrenceville, New Jersey 08648-5218
                            For deliveries:
                            --------------
                            997 Lenox Drive
                            Building 3, Suite 210
                            Lawrenceville, New Jersey 08648-5218
                            Attention:    Allen Bloom, Esq.
                            Telephone:    **

                                       37
<PAGE>

          **Certain information on this page has been omitted and filed
          separately with the Commission. Confidential treatment has been
          requested with respect to the omitted portions.

                            Telecopy:     **

     11.5. Force Majeure.  Neither Party shall be liable to the other for
           -------------
failure or delay in the performance of any of its obligations under this
Agreement for the time and to the extent such failure or delay is caused by
earthquake, riot, civil commotion, terrorism, war, hostilities between nations,
governmental law, order or regulation, embargo, action by the government or any
agency thereof, act of God, storm, fire, accident, labor dispute or strike,
sabotage, explosion or other similar or different contingencies, in each case,
beyond the reasonable control of the respective Party. The Party affected by
force majeure shall provide the other Party with full particulars thereof as
soon as it becomes aware of the same (including its best estimate of the likely
extent and duration of the interference with its activities), and will use its
best endeavors to overcome the difficulties created thereby and to resume
performance of its obligations as soon as practicable. If the performance of any
obligation under this Agreement is delayed owing to a force majeure for any
continuous period of more than six (6) months, the Parties hereto shall consult
with respect to an equitable solution including the possible termination of this
Agreement.

     11.6. Independent Contractors.  Nothing contained in this Agreement is
           -----------------------
intended implicitly, or is to be construed, to constitute GSK or Unigene as
partners or joint venturers in the legal sense. No Party hereto shall have any
express or implied right or authority to assume or create any obligations on
behalf of or in the name of any other Party or to bind any other Party to any
contract, agreement or undertaking with any Third Party.

     11.7. Other Obligations.  Except as expressly provided in this Agreement or
           -----------------
as separately agreed upon in writing between Unigene and GSK, each Party shall
bear its own costs incurred in connection with the implementation of the
obligations under this Agreement.

     11.8. Severability.  If any of the terms or provisions of this Agreement
           ------------
are in conflict with any applicable statute or rule of law, then such terms or
provisions shall be deemed inoperative to the extent that they may conflict
therewith and shall be deemed to be modified to conform with such statute or
rule of law. In the event that the terms and conditions of this Agreement are
materially altered as a result of the above, the Parties will renegotiate the
terms and conditions of this Agreement to resolve any inequities

     11.9. Further Assurances.  At any time or from time to time on and after
           ------------------
the date of this Agreement, either Party shall at the request of the other Party
(i) deliver to the requesting Party such records, data or other documents
consistent with the provisions of this Agreement, (ii) execute, and deliver or
cause to be delivered, all such consents, documents or further instruments of
assignment, transfer or license, and (iii) take or cause to be taken all such
actions, as the requesting Party may reasonably deem necessary or desirable in
order for the requesting Party to obtain the full benefits of this Agreement and
the transactions contemplated hereby.

                                       38
<PAGE>

     11.10. Entire Agreement.  This Agreement constitutes the entire agreement,
            ----------------
both written or oral, with respect to the subject matter hereof, and supersedes
and terminates all prior or contemporaneous understandings or agreements,
whether written or oral, between GSK and Unigene with respect to such subject
matter, including, but not limited to, that Confidential Disclosure Agreement
dated October 18, 2001. No terms or provisions of this Agreement shall be varied
or modified by any prior or subsequent statement, conduct or act of either of
the Parties, except that the Parties may amend this Agreement by written
instruments specifically referring to and executed in the same manner as this
Agreement.

     11.11. Headings.  The captions to the Articles and Sections hereof are not
            --------
a part of this Agreement, but are included merely for convenience of reference
only and shall not affect its meaning or interpretation.

     11.12. Counterparts.  This Agreement may be executed in any number of
            ------------
counterparts, each of which shall be deemed an original and all of which
together shall constitute one and the same instrument.

                    [THIS SECTION LEFT INTENTIONALLY BLANK]

                                       39
<PAGE>

     IN WITNESS WHEREOF, the Parties hereto have caused this License Agreement
to be duly executed by their authorized representatives as of the Effective
Date.

UNIGENE LABORATORIES, INC.                SMITHKLINE BEECHAM CORPORATION, a
                                          GlaxoSmithKline Company

By:  /s/ Jay Levy                        By:  /s/ J.P. Garnier
     ---------------------------------        -------------------------------
Name:  Jay Levy                          Name:  J.P. Garnier
       -------------------------------          -----------------------------
Title:  Chairman of the Board            Title:  CEO GSK
        ------------------------------           ----------------------------

                                       40
<PAGE>

**Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                  APPENDIX A
                                  ----------
                             UNIGENE PATENT RIGHTS
                             ---------------------

<TABLE>
<CAPTION>
**
------------------------------------------------------------------------------------------------------------------------------------
           **                     **                 **                 **                **                **               **
------------------------------------------------------------------------------------------------------------------------------------
          <S>                     <C>                <C>                <C>               <C>               <C>              <C>
           **                     **                 **                 **                **                **               **
------------------------------------------------------------------------------------------------------------------------------------
           **                     **                 **                 **                **                **               **
------------------------------------------------------------------------------------------------------------------------------------
           **                     **                 **                 **                                                   **
------------------------------------------------------------------------------------------------------------------------------------
           **                     **                 **                 **                                                   **
------------------------------------------------------------------------------------------------------------------------------------
           **                     **                 **                 **                                                   **
------------------------------------------------------------------------------------------------------------------------------------
           **                     **                 **                 **                                                   **
------------------------------------------------------------------------------------------------------------------------------------
           **                     **                 **                 **                                  **               **
------------------------------------------------------------------------------------------------------------------------------------
</TABLE>

                                       41
<PAGE>

**Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------------------------------------
           **                     **                  **                   **                **               **               **
------------------------------------------------------------------------------------------------------------------------------------
           <S>                    <C>                 <C>                  <C>               <C>              <C>              <C>
           **                     **                  **                   **                                                  **
------------------------------------------------------------------------------------------------------------------------------------
           **                     **                  **                   **                                                  **
------------------------------------------------------------------------------------------------------------------------------------
           **                     **                  **                   **                                                  **
------------------------------------------------------------------------------------------------------------------------------------
           **                     **                  **                   **                                                  **
------------------------------------------------------------------------------------------------------------------------------------
           **                     **                  **                   **                **               **               **
------------------------------------------------------------------------------------------------------------------------------------
           **                     **                  **                   **                                                  **
------------------------------------------------------------------------------------------------------------------------------------
           **                     **                  **                   **                                                  **
------------------------------------------------------------------------------------------------------------------------------------
           **                     **                  **                   **                                 **               **
------------------------------------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------------------------------------
           **                     **                  **                   **                **               **               **
------------------------------------------------------------------------------------------------------------------------------------
</TABLE>

                                       42
<PAGE>

**Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------------------------------------
          **                  **                 **                 **                     **                 **                 **
------------------------------------------------------------------------------------------------------------------------------------
          <S>                 <C>                <C>                <C>                    <C>                <C>                <C>
          **
------------------------------------------------------------------------------------------------------------------------------------
          **
------------------------------------------------------------------------------------------------------------------------------------
          **                  **                 **                 **                                                           **
------------------------------------------------------------------------------------------------------------------------------------

------------------------------------------------------------------------------------------------------------------------------------
          **                  **                 **                 **                                                           **
------------------------------------------------------------------------------------------------------------------------------------
          **                  **                 **                 **                                                           **
------------------------------------------------------------------------------------------------------------------------------------
          **                  **                 **                 **                                                           **
------------------------------------------------------------------------------------------------------------------------------------
</TABLE>

                                      43

<PAGE>

**Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------------------------------------
    **                     **                 **                 **                    **                  **                **
------------------------------------------------------------------------------------------------------------------------------------
<S>                        <C>                <C>                <C>                   <C>                 <C>              <C>

 **
------------------------------------------------------------------------------------------------------------------------------------
</TABLE>

                                       44
<PAGE>

     **Certain information on this page has been omitted and filed separately
     with the Commission. Confidential treatment has been requested with respect
     to the omitted portions.

<TABLE>
    **
----------------------------------------------------------------------------------------------------------------------------------
        **                **                 **                 **                   **                 **               **
----------------------------------------------------------------------------------------------------------------------------------
       <S>                <C>                <C>                <C>                  <C>                <C>              <C>
        **                **                 **                 **                                                       **
        **                **                 **                 **                                                       **
        **                **                 **                 **                                                       **
        **                **                 **                 **                                                       **
        **                **                 **                 **                                                       **
        **                **                 **                 **                                                       **
        **                **                 **                 **                   **                 **               **
        **                **                 **                 **                                                       **
----------------------------------------------------------------------------------------------------------------------------------
        **                **                 **                 **                   **                 **               **
----------------------------------------------------------------------------------------------------------------------------------
</TABLE>

                                       45
<PAGE>

     **Certain information on this page has been omitted and filed separately
     with the Commission. Confidential treatment has been requested with respect
     to the omitted portions.

--------------------------------------------------------------------------------
 **          **          **          **                     **         **
 **          **          **          **                                **
 **          **          **          **          **         **         **
 **          **          **          **          **         **         **
 **          **          **          **          **         **         **
 **          **          **          **                                **
 **          **          **          **          **         **         **

            --------------------------------------------------------------------
 **          **          **          **          **         **         **
 **          **          **          **          **         **         **
 **          **          **          **          **         **         **
 **          **          **          **          **         **         **
 **          **          **          **          **         **         **

                                       46
<PAGE>

     **Certain information on this page has been omitted and filed separately
     with the Commission. Confidential treatment has been requested with respect
     to the omitted portions.

 **          **          **          **          **         **         **
 **          **          **          **          **         **         **
 **          **          **          **          **         **         **
 **          **          **          **          **         **         **

            --------------------------------------------------------------------
 **
 **          **          **          **          **         **         **
 **          **          **          **          **         **         **
 **          **          **          **          **         **         **
 **          **          **          **                                **

                                       47
<PAGE>

     **Certain information on this page has been omitted and filed separately
     with the Commission. Confidential treatment has been requested with respect
     to the omitted portions.

 **          **          **          **          **         **         **
 **          **          **          **                                **
 **          **          **          **          **         **         **
 **          **          **          **          **         **         **
 **          **          **          **          **         **         **
 **          **          **          **          **         **         **
 **          **          **          **          **         **         **

                                       48
<PAGE>

     **Certain information on this page has been omitted and filed separately
     with the Commission. Confidential treatment has been requested with respect
     to the omitted portions.

**         **            **          **                      **
**         **            **          **                      **
**         **            **          **                      **
**         **            **          **                      **
**         **            **          **                      **
**         **            **          **                      **

                                       49
<PAGE>

     **Certain information on this page has been omitted and filed
     separately with the Commission. Confidential treatment has been requested
     with respect to the omitted portions.

**         **            **          **                      **
**         **            **          **                      **
**         **            **          **                      **
**         **            **          **                      **
**         **            **          **                      **

**         **            **          **                      **
**         **            **          **                      **

_______________
/1/ **

                                       50
<PAGE>

     **Certain information on this page has been omitted and filed separately
     with the Commission. Confidential treatment has been requested with respect
     to the omitted portions.

**         **          **           **         **        **         **
**         **          **           **                   **         **
**         **          **           **         **        **         **
**         **          **           **         **        **         **
**         **          **           **         **        **         **
**         **          **           **         **        **         **
**         **          **           **         **        **         **

                                       51
<PAGE>

**Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                  APPENDIX B
                                  ----------

              WORKPLAN OF UNIGENE ACTIVITIES AND FTE REQUIREMENTS
              ---------------------------------------------------
--------------------------------------------------------------------------------
     ACTIVITY DESCRIPTION       ESTIMATED      DURATION    UNIGENE     MAXIMUM
                                  PERIOD                    STAFF        COST
                                                                       ($'000)

**                                  **             **         **          **
**                                  **             **         **          **
**                                  **             **         **          **
**                                  **             **         **          **
**                                  **             **         **          **
**                                  **             **         **          **
**                                  **             **         **          **
                                               ----------              -------
**                                                 **                     **
**
**                                  **             **         **          **
**
**                                  **             **         **          **

-------------------------------------------------------------------------------

                                       52
<PAGE>

**Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                  APPENDIX C:
                                  -----------
                   Unigene Know-How and Technology Transfer
                   ----------------------------------------
1.      **

2.      **

3.      **

4.      **

5.      **

6.      **

7.      **

8.      **

9.      **

10.     **

11.     **

12.     **

13.     **

14.     **

15.     **

16.     **

17.     **

                                       53
<PAGE>

**Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

18.     **

19.     **

20.     **

21.     **

22.     **

23.     **

24.     **

25.     **

26.     **

**

**

..              **

..              **

..              **

                                       54
<PAGE>

                                  APPENDIX D
                                  ----------
           ENCUMBRANCES TO LICENSED TECHNOLOGY AS OF EFFECTIVE DATE
           --------------------------------------------------------

     Patent Security Agreement between Unigene Laboratories and Jay Levy dated
March 13, 2001.

                                       55Exhibit 10.72.5

                                    AMENDMENT

         This Amendment is agreed to as of March 31, 2002 by and between
Hydrocarbon Technologies, Inc., a New Jersey corporation ("HTI"), and Headwaters
Incorporated, a Delaware corporation ("Headwaters"), and amends that Share
Exchange Agreement made and entered into as of May 2, 2001 by and among HTI,
Headwaters and certain former stockholders of HTI referred to as "Transferors"
named therein (the "Exchange Agreement") and the Agreement and Plan of
Reorganization dated as of May 2, 2001 by and among HTI, Headwaters and the "HTI
Founders" named therein (the "Merger Agreement"). This Amendment is subject to
approval by at least a majority in interest of all of the Transferors (the
"Majority Approval").

                                    RECITALS:

         WHEREAS, the EBITDA-related Milestone under the Exchange Agreement has
not been achieved as of December 31, 2001 and the Shenhua and PetroChina
Milestones under the Exchange Agreement have not been satisfied as of March 31,
2002;

         WHEREAS, under the Exchange Agreement, the holders of a majority of the
HTI Common Stock prior to the merger who constitute Transferors under the
Exchange Agreement may amend the Exchange Agreement and the Merger Agreement
together with Headwaters and HTI; and

         WHEREAS, the parties wish to provide to the Transferors a full and
complete payment at this time of 60% of the First Contingent Payment under the
Exchange Agreement and a release of his or her escrowed shares and cash, in
exchange for full and complete settlement of all future Contingent Payments
which could potentially be earned under the Exchange Agreement.

         NOW, THEREFORE, the undersigned agree hereto as follows:

         1. Amendment. Subject to the Majority Approval, Headwaters and HTI
agree to the terms of the Amendment set forth in Exhibit A, which are
incorporated by reference herein. The aggregate number of shares of Headwaters
Common Stock and the amount of cash that the Transferors would receive as a
result of the Amendment, including the payment of 60% of the First Contingent
Payment and the escrowed amount, is set forth in Exhibit B. HTI agrees to
solicit the approval of the Amendment by the Transferors pursuant to the
Amendment. At Headwaters' discretion, the percentage of shares approval of the
Transferors may be increased, but not to exceed the number of shares
collectively held by the Representative and by a majority of interest of the
remaining Transferors.

         2. Other. All other provisions of the Exchange Agreement and Merger
Agreement shall remain in effect except as amended herein. All capitalized terms
not otherwise defined herein have the meanings set forth in the Exchange
Agreement or the Merger Agreement.

         3. Governing Law. This Amendment shall be governed by and construed in
accordance with the laws of the State of New Jersey.

         IN WITNESS WHEREOF, the parties hereto agree as of the date first above
written.

                                                  HEADWATERS INCORPORATED

                                                  By /s/ Kirk A. Benson
                                                    ----------------------------
                                                  Title CEO

                                                  HYDROCARBON TECHNOLOGIES, INC.

                                                  By /s/ Alfred G. Comolli
                                                    ----------------------------
                                                  Title President

<PAGE>

                                    EXHIBIT A

                          Form of Transferor Amendment

                                    AMENDMENT

         This Amendment is agreed to by the undersigned former shareholder of
Hydrocarbon Technologies, Inc., a New Jersey corporation ("HTI"), who is a
"Transferor," pursuant to that Share Exchange Agreement made and entered into as
of May 2, 2001 by and among HTI, Headwaters Incorporated, a Delaware corporation
("Headwaters"), and the Transferors (the "Exchange Agreement") and is an HTI
Stockholder pursuant to the Agreement and Plan of Reorganization dated as of May
2, 2001 by and among HTI, Headwaters and the "HTI Founders" named therein (the
"Merger Agreement"). This Amendment amends the Exchange Agreement, subject to
approval by at least a majority in interest of all of the Transferors or such
greater percentage as Headwaters may require, but not to exceed 80% (the
"Majority Approval"). The undersigned's approval hereto is conditioned upon the
fact that Headwaters and HTI have already agreed to this Amendment, subject to
the Majority Approval.

                                    RECITALS:

         WHEREAS, the EBITDA-related Milestone under the Exchange Agreement has
not been achieved as of December 31, 2001 and the Shenhua and PetroChina
Milestones under the Exchange Agreement have not been achieved as of March 31,
2002;

         WHEREAS, under the Exchange Agreement, the holders of a majority of the
HTI Common Stock prior to the merger who constitute Transferors under the
Exchange Agreement may amend the Exchange Agreement together with Headwaters and
HTI; and

         WHEREAS, the undersigned Transferor wishes to receive a full and
complete payment at this time of 60% of the First Contingent Payment under the
Exchange Agreement and a release of his or her escrowed shares and cash in
exchange for full and complete settlement of all future Contingent Payments
which could potentially be earned under the Exchange Agreement.

         NOW, THEREFORE, the undersigned agrees as follows:

         1. Contingent Payments. The Exchange Agreement is hereby amended
(including the deletion in their entirety of Sections 1.3(c)(ii) and (iii) and
Section 1.3(d) and the defined terms contained therein) such that all
requirements relating to the Contingent Payments shall be satisfied in full upon
(a) the payment by Headwaters of an amount of cash and Headwaters Common Stock
equal to 60% of the First Contingent Payment, and (b) immediate release of the
cash and shares of Headwaters Common Stock currently held in escrow pursuant to
the Exchange Agreement and the Merger Agreement (rather than the August 28, 2003
release date provided therein). The number of shares of Headwaters Common Stock
and the amount of cash that the undersigned would receive as a result of the
Amendment, including the payment of the First Contingent Payment and the
escrowed amount, is set forth below. The undersigned acknowledges and agrees
that the amounts paid at Closing, and the payments set forth below in connection
with the escrow and the First Contingent Payment were adjusted from the Exchange
Agreement calculations, as approved by a majority in interest of the
Transferors, in order to decrease the amount of cash paid and increase the
number of shares of Headwaters Common Stock paid and maintain the percentage
required to maintain tax-free reorganization treatment of the transactions.

<PAGE>

         2. Release From Liability.

         (a) Headwaters has acknowledged and agreed that all liabilities of the
Transferors (except for those persons who were directors and officers of HTI at
the Closing, whose liabilities are limited to his or her total Exchange
Consideration, escrow amount and Contingent Payments earned, and except, for all
Transferors, those liabilities in connection with any breach of Section 2.2 of
the Merger Agreement relating to HTI's capital structure), are released at the
time of the release of cash and shares of Headwaters Common Stock from escrow.

         (b) The undersigned agrees that the above determination of the
Contingent Payments is final for all purposes under the Exchange Agreement and
with Majority Approval will be made on behalf of all the Transferors and that,
following such payment, none of the Transferors will have a claim pursuant to
the Exchange Agreement, Merger Agreement or any other provision of any other
agreement relating to Contingent Payments or the escrow amount. The undersigned
acknowledges and agrees that Headwaters has not taken any action which impaired
achievement of the Milestones by HTI or materially modified or altered the
business plan or operations of HTI. In consideration of the payments set forth
above, Transferor voluntarily, knowingly and willingly releases and forever
discharges Headwaters, HTI, their predecessors, subsidiaries and affiliates,
together with each of those entities' respective officers, directors, partners,
shareholders, employees and agents, from any and all claims and rights of any
nature whatsoever which Transferor (including his or her heirs and assigns) now
has or in the future may have against them to the date of this Amendment
relating to payments owed under the Exchange Agreement.

         3. Information Provided. The undersigned hereby acknowledges and agrees
that he or she has been advised about the matters set forth on Exhibit A and has
been furnished or given all financial and other information regarding HTI as the
undersigned has deemed necessary for the full and complete evaluation of whether
to enter into this Amendment, including the assessment of the likelihood of
future achievement of a portion of the First Contingent Payment and all or a
portion of the Second Contingent Payment.

         4. No Liability of Representative. The undersigned reaffirms the
agreement in the Exchange Agreement that the individuals constituting the
Representative of the Transferors (Alfred Comolli, David Tanner and L.K. (Theo)
Lee) will not be liable for any act done or omitted as Representative under the
Exchange Agreement while acting in good faith and such act is not an act of
willful misconduct in the performance of his obligations, and in addition agrees
that the persons above constituting the Representative shall have no liability,
and the undersigned shall take no legal actions against them, with respect to
their actions in negotiating the Amendment on behalf of the Transferors or in
agreeing to the Amendment as Transferors.

         5. Other. All other provisions of the Exchange Agreement and Merger
Agreement shall remain in effect except as amended herein. All capitalized terms
not otherwise defined herein have the meanings set forth in the Exchange
Agreement. HTI and Headwaters and their directors, officers, shareholders and
employees may rely on this Amendment for all purposes.

         6. Governing Law. This Amendment shall be governed by and construed in
accordance with the laws of the State of New Jersey.

                                       2
<PAGE>

         The undersigned agrees as the date below.

TRANSFEROR

______________________________________________________________

Printed Name _________________________________________________

Address:______________________________________________________

______________________________________________________________

Dated:______________________________________

Number of shares of Headwaters Common Stock and cash to be received if this
Amendment receives Majority Approval:

First Contingent Payment: __________ shares $ ________ cash

Release from Escrow: __________ shares $ ________ cash

                                       3
<PAGE>

                                    EXHIBIT A

         In addition to any information provided by HTI and Headwaters
representatives, the undersigned has been advised of the following. The
undersigned may request any other information required to make a decision to
enter into the Amendment.

         1. Possibility of Earning the Contingent Payments. HTI's 2001 Actual
EBITDA (earnings before interest, tax, depreciation and amortization) was less
than 80% of the required 2001 Projected EBITDA of $3,670,000, so no
EBITDA-related First Contingent Payment can be earned under the Exchange
Agreement.

         The Exchange Agreement provides that if both the Shenhua or PetroChina
agreement are signed by March 31, 2003, 50% of the First Contingent Payment
could be earned. However, the Exchange Agreement provides that the Shenhua
agreement must contain terms "that can reasonably be expected to result in
license revenues consistent with the Business Plan agreed to by HTI and
Headwaters." The current form of Shenhua agreement being negotiated provides for
terms which may not satisfy the test set forth in the Exchange Agreement.

         To earn all of the Second Contingent Payment (equal in amount of cash
and Headwaters Common Stock to the First Contingent Payment), 2002 Actual EBITDA
must equal or exceed $3,362,000. HTI's EBITDA for the first two months of 2002
was a loss of $ 870,000, and the expected loss for March is in excess of
$500,000. The Exchange Agreement provides that part of the Second Contingent
Payment may be earned on a sliding scale to the extent that 2002 Actual EBITDA
exceeds $2,689,600 (80% of the required 2002 Projected EBITDA of $3,362,000).
For example, if 2002 Actual EBITDA is $2,689,600 or less, then the Second
Contingent Payment will be zero; if $2,857,700 (85%), the amount earned will be
25% of the Second Contingent Payment; if $3,025,800 (90%), the amount earned
will be 50% of the Second Contingent Payment; if $3,193,900 (95%), the amount
earned will be 75% of the Second Contingent Payment. To meet any of the above
tests, the loss for the first quarter will need to be made up from 2002
revenues.

         2. Escrow Issues. The Escrow Agreement provides that Headwaters Common
Stock and cash in escrow will be held until August 28, 2003, the second year
anniversary of the closing of the Exchange Agreement and the Merger Agreement.
No claims against the escrow have been made to date.

         3. Arrangements with HTI Management. HTI and Headwaters have determined
that, subject to the restructuring of the Exchange Agreement under the
Amendment, Al Comolli and David Tanner will be terminated from employment, and
Theo Lee will be CEO of HTI. Under their Employment Agreements, each would be
eligible for severance in the amount of their salary through September 2003.
However, each of Comolli and Tanner have agreed to give up their severance;
Tanner will provide consulting services for a period of time. Comolli and Tanner
will also receive reimbursement for payments for their health benefits through
September 2003, as required by their employment agreements. Each of Comolli,
Tanner and Lee will be indemnified by Headwaters in connection with their
activities in negotiating this Amendment, in addition to the indemnification
rights they currently have under their employment arrangements and the bylaws
and charters of HTI and Headwaters and applicable law.

                                       4
<PAGE>

                                    EXHIBIT B
                                List of Payments

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00038-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00038-of-00352.parquet"}]]